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Abstract 
 
BAD is a Central Player in Cell Death and Cell Cycle Regulation in Breast Cancer 
Cells 
The estrogen, 17-β estradiol (E2) can stimulate proliferation or induce differentiation or 
death depending on the cell context.  In MCF 7 cells, an estrogen receptor (ER) positive 
human breast cancer cell line, E2 has been shown to stimulate cell proliferation and may 
have an anti-apoptotic effect.  E2 rapidly activates mitogen activated protein kinases 
(MAPKs) in mammalian cells in an ER dependent fashion. The mechanisms underlying 
and the physiological significance of the signaling through MAPK remain to be 
determined. This signal pathway may represent a potential mechanism by which E2 
regulates cell proliferation, growth as well as apoptosis.  Recent observation of Raf-1 
kinase (which relays signals from cell surface receptor tyrosine kinase to MAPKs) 
activation by E2 in MCF 7 cells explained a possible link between cell surface and 
intracellular components of the signaling pathway.  PI-3 kinase and its down stream 
member protein kinase B (PKB/Akt) have been shown to be strongly involved in 
mitogenic and anti-apoptotic signaling in MCF 7 cells.    
Chemical and biological inhibition of PI-3 kinase diminished E2 supported cell 
survival and concomitant Akt, MAPK (ERK) and its down stream target p90RSK 
activities.  On the other hand, interference of endogenous Ras with a dominant negative 
construct abolished signal mechanisms involving ERK as well as Akt.  These 
observations suggested that Ras/ERK and PI-3 Kinase pathways could operate as 
separate entities or cross talk and cooperate to enhance survival or impede apoptosis in 
MCF 7 cells in the presence of E2.   
BCL2 family proteins play critical decision-making roles during apoptosis.  BH3 
domain only, pro-apoptotic member, BAD has been intensively investigated for its 
contribution in regulation of apoptosis at the mitochondrial level.  Post-translational 
phosphorylation modulates BAD’s function and, most survival factors impose inhibitory 
phosphorylations on BAD via active Akt and MAPK pathways.   
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E2 rapidly induces Akt and ERK signaling pathways resulting in phosphorylation 
of BAD on two serine residues, and abolishes apoptosis in response to a variety of stimuli 
in MCF-7 cells.  Therefore, we hypothesized that E2 targets BAD for its anti-apoptotic 
effect.  Data presented clearly show that E2 effects are at least partly mediated via Ras 
originated ERK/p90RSK and PI-3 kinase/Akt pathways that add inhibitory phosphate 
groups onto corresponding serine 75 and 99 residues of BAD there by inactivating its 
pro-apoptotic tendencies.  We demonstrate the significance of BAD and its functional 
serine residues in E2 mediated anti-apoptosis with studies conducted with anti-sense 
mRNA and phosphorylation site mutants of BAD.  Over-expression of wild type or 
phosphorylation site mutant of BAD did not enhance the basal cell death, which was 
remarkably lessened by the inhibition of endogenous BAD.  E2 could rescue cells from 
TNFα induced death in control cultures and in wild type BAD transfected cells but not in 
phosphorylation site mutant BAD expressing cells.  This observation agrees with 
previous studies that demonstrate the importance of BAD’s phosphorylation sites in 
growth factor mediated cell protection.  This study shows for the first time that E2 is an 
anti-apoptotic agent in breast cancer cells whose response is mediated by non-genomic 
cytoplasmic signal networks that converge on BAD in turn regulating the mitochondrial 
membrane potential change.     
When transiently over-expressed, wild type or dual phosphorylation site mutant of 
BAD did not induce apoptosis, as observed in the first part of this study, but the rate of 
growth of these cells was remarkably low compared to the untransfected or control vector 
transfected cells.  This suggested that the presence of extra amount of BAD could reduce 
the growth of MCF-7 cells.  Similar phenomenon have been reported with the 
overexpression of BCL2 in malignant as well as normal epithelial cells.  When over 
expressed, BCL2 arrests cell cycle in G0/G1 phase and this effect appears to depend on 
the amino terminal BH4 domain.  Interestingly in a variety of epithelial cell types, 
endogenous BCL2 was shown to localize to the chromosomes of mitotic nuclei.  This 
pattern of BCL2 expression is considered to be indicative of its special role in cell 
proliferation.   
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We hypothesized that BAD also exhibits a cell cycle related function in breast 
cancer epithelial cells, which was tested in the second part of this study.  We evaluated 
the distribution pattern of nuclear BAD in several breast cancer cell lines.  BAD 
overexpression lessened cyclin D1protein levels that agreeably correlate with the G1-S 
transition block observed.  Cyclin D1 regulation by BAD was assayed at the 
transcriptional level using a luciferase reporter under the control of the cyclin D1 
promoter.  In asynchronous cells and in synchronous and E2 treated cells, BAD over-
expression significantly reduced the cyclin D1 reporter activity.  Overexpression of a 
dual phosphorylation site mutant of BAD did not alter the cyclin D1 expression pattern or 
the cell cycle progression suggesting an involvement of these serine residues in BAD’s 
nuclear functions.  Furthermore, the BH3 domain deletion mutant and the S91A mutant, 
both of which carry intact S75 and S99 residues, exerted inhibitory effects similar to that 
of wild type BAD.  
Wild type BAD overexpression as well as BAD depletion from nuclear extracts 
diminished the labeled AP-1/TRE DNA binding with the nuclear factors.  This 
demonstrates that BAD is capable of binding and sequestering some components from 
the nuclear extracts which bind with AP-1/TRE element.  Collectively our data suggest 
that in addition to pro-apoptotic functions, BAD regulates the cell cycle at least partly via 
AP-1/TRE element.  These functions appear to depend on its S75 and S99 
phosphorylation status that are also the targets of pro-survival mechanisms.  Further, 
these results also suggest that the AP-1 transcription regulation by BAD is kept at its 
minimal level in normal cells as a result of the fine balance of its phosphorylation state.     
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Chapter 1  
Signal Pathways that Mediate 17-β Estradiol Induced Anti-apoptosis in 
Breast Cancer Cells 
1.1 Introduction 
1.1.1 Cancer 
Cancer cells are characterized by two heritable properties; they (i) reproduce in defiance 
of normal restraints, and (ii) invade and colonize surrounding tissue and distant sites 
constituting the phenomenon, metastasis.  Fundamental properties of malignancy are 
encoded in genes of the cancer cell, as evident by the inheritance of malignant traits by its 
progeny.  Studies of genetic markers in cancers indicate a given human tumor is derived 
from a single cell (e.g. expression of unique immunoglobulin molecules in lymphomas 
and myelomas, translocation of chromosomes 9 and 22 (Philadelphia chromosome) in 
chronic myelogenous leukemia).  However, further genetic changes as well as other 
environmental factors could result in a heterogeneous population of cancer cells in a 
given tumor and this heterogeneity may affect many aspects of cancer development i.e. 
invasiveness, resistance to tumor therapy and metastatic properties, hence the tumor 
progression.    
Much of current cancer research is directed to the identification and 
characterization of genes whose products are involved in the transformation of a normal 
to a malignant cell.  These studies led to the identification of oncogenes, where a 
mutation causes a change in a normal cellular protein that could lead to malignant change 
in the cell.  These genes are dominantly acting since only one copy of the gene has to 
undergo the mutation.  Many of these gene products are important in the normal 
transmission of growth-promoting signals from cell surface to the nucleus (e.g. src, ras), 
transcription regulation (e.g. myc, c-jun), or regulation of cell death (e.g. bcl2).  The other 
class of genes, tumor suppressors, acts to suppress the malignant transformation in 
normal cells (e.g. Rb, p53, BRCA1 and 2).  Both copies of the tumor suppressor gene 
must be lost, mutated or inactivated for malignant transformation.  In normal tissue, there 
is a balance between cell proliferation and cell death.  In tumors, this balance is disturbed 
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perhaps because of genetic defects that lead to abnormal cell proliferation and death.  
Aberrant cell proliferation and death rarely coincide as does the occurrence of cancer.  
Increased proliferation consequently triggers cell death and the reduced cell death is not 
significance in the absence of enhanced proliferation (103).  This natural interdependency 
of the two key mechanisms keeps the tissue balanced.  Accumulation of genetic damages 
in cells hinders their ability to restrain or counteract abnormal cellular processes.  
Acquisition of independency from mitogenic stimuli and noncompliance to growth 
inhibitory signals could be the result of such genetic mutations.  Telomere erosion, which 
sets control for endless cell division is the next obstacle that sustained cell proliferation 
has to overcome.  Telomeres are the long non-transcribed regions at the ends of 
chromosomes.  As a result of repeated DNA replication these structures shortens and this 
phenomenon is termed as telomere erosion.  The enzyme that repairs the eroded 
telomeres, telomerase is expressed in limited fashion in somatic cells; therefore the 
somatic cells are allowed only a limited number of cell divisions (105).  Telomerase up-
regulation has been observed in cancer (18).      
Characterization of cell proliferation and death in cancer has provided the 
information that contrary to general belief, tumor cells usually proliferate more slowly 
than cells in normal tissues, such as the intestinal epithelium and bone matrix.  A 
relatively small proportion of tumor cells may retain the capacity for unlimited 
proliferation and these stem cells are the important targets of cancer therapy.  
Furthermore, tumors have a high rate of cell death perhaps as a result of limited supply of 
nutrients, through the process of programmed cell death and /or necrosis (72).  Also, the 
over-expression of oncogenes has been shown to induce apoptosis in tumors 
(75,122,151).      
It has been suggested that immune surveillance may eradicate some tumors before 
their clinical detection.  Expression of ‘non-self’ molecules such as the products of 
mutated oncogenes, which differ from those in normal cells, could promote an immune 
rejection response.  Therefore, the tumors that either do not express these ‘non-self’ 
molecules or have mechanisms allowing them to evade the immune rejection response 
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may continue to grow (1).  This type of information has led to the efforts to devise 
therapies that might induce tumor rejection by the host.   
In solid tumors there are interactions between the constituent cells and the extra 
cellular matrix (ECM).  These interactions may be modulated by growth factors and 
hormones that interact with specific receptors and propagate signal and gene expression, 
and adhesion molecules that interact with ECM components and initiate intracellular 
signaling (46,181,215).   The ECM provides the surface for the cell attachment and a 
barrier for cell movement.  Therefore, breakdown of extra cellular components through 
secretion of proteolytic enzymes (e.g. metalloproteinases, Cathepsins), which is thought 
to be an important mechanism in metastasis (229), may also assist in invasion, growth 
and the angiogenesis of a tumor.  The inhibition of these proteases has been recognized as 
potential strategy to suppress tumor growth (88).  Further, proper attachment of 
transformed as well as untransformed mammary epithelial cells to the ECM was shown 
to enhance their anti-apoptotic capacity.  This acquired resistance to apoptosis depends, at 
least in part on NFκB mediated signaling, which was activated in this system by the 
interaction of epithelial integrin and the ECM (283).     
 In order to sustain the growth, a solid tumor has to elicit the proliferation of blood 
vessels that provide nutrition to the cancer cells and remove catabolic products.  This 
process of angiogenesis is stimulated by the release of several growth factors from tumor 
cells as well as the surrounding normal cells.  Vascular endothelial growth factor (VEGF) 
has been shown to vastly contribute to this process.  The synthesis and release of VEGF 
is stimulated by the hypoxic environment (223).  Upregulation of VEGF and 
angiogenesis has also been observed in response to constitutive activation of other 
oncogenic proteins (e.g. EGFR, Raf, MEK, PI3K) acting at various levels on the Ras 
signaling pathway (219).  Interestingly, a stronger expression of VEGF was observed in 
the surrounding stroma but not in the tumor in an animal model (97).  This finding that 
the VEGF promoter of non-transformed cells is strongly activated by the tumor 
microenvironment may point to a need to analyze and understand the stromal cell 
collaboration in tumor angiogenesis.   
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While clinical observation has divided tumor development into a number of discrete 
categories of severity (benign, malignant, metastatic), the underlying biology can be 
described as a process of many changes.  The genetic changes can affect the cell’s growth 
potential, and the cells with such changes are selected for (or against) by the conditions 
they are exposed to.  Increasing knowledge of signal transduction pathways in cells has 
demonstrated that many aspects of cell function are controlled by a balance of positive 
and negative signals received from inside and the outside of the cell.  Thus the lack of 
ability or increased ability to respond to a specific signal may allow the cell to proliferate 
in the face of other signals that would normally prevent such proliferation.  Cancer 
treatment can be considered as adding negative signals to the cellular environment.  The 
process of genetic change may give rise to a subpopulation of cells that have evolved 
varied mechanisms of drug resistance, and these cells could survive and re-grow the 
tumor following chemotherapy.  The genetic evolution of cancer cells and the signal that 
the cells receive from their extra cellular environment therefore could play critical roles 
in the growth and treatment of cancers (1).                          
 
1.1.2 Estrogen 
Synthesis, Metabolism and Physiological Importance  
Estrogens, an important class of steroid hormones, influence growth, differentiation and 
functions of many target tissues.  All naturally occurring estrogens (estrone, estradiol and 
estriol) are C18 steroids secreted by the theca interna and granulosa cells of the 
developing ovarian follicle, corpus luteum as well as the placenta.  Estrogens are also 
produced by aromatization of androgens in adipose tissue, liver, skin and in breast 
epithelial cells.  Both estrogens and precursor androgens are derived from cholesterol.  
The most potent naturally occurring estrogen, 17-β estradiol (E2) is found in both free 
and protein bound forms in the circulation (Figure 1.1.2.1).  After synthesis, E2 is 
secreted into the blood stream where it binds with sex-hormone-binding globulin and 
albumin.  Free estrogens diffuse into target tissues to exert their specific genomic or non-
genomic effects.  Enzymatic catabolism of estrogens yields the hydroxyl-estrogens and 
methoxy-estrogens (107).  In the liver, estrogens are conjugated to sulfate or gluconate 
4
Promotes 
breast cancer
Modified from NEJM 346: 340-352
Figure 1.1.2.1
Synthesis, metabolism and physiological importance of estrogen
See text for details
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and made water-soluble.  Then they are excreted by billiary secretion and a major part of 
it is reabsorbed prior to urinary passage (2).       
Besides stimulating development and maturation of the female reproductive 
structures and secondary sexual characteristics, estrogens are necessary for cyclic 
endometrial changes that are important for reproduction, development of breast tissue, 
health of the skin and bone homeostasis.  Estrogenic effects on blood coagulation, 
endothelial cells, intestinal motility, cholesterol metabolism and sodium and water 
conservation by renal tissue have also been appreciated giving estrogen a remarkable 
importance in the normal physiology (123,228).  Importance of estrogen in male fertility, 
specifically to sperm count was reported recently.  This study focused on the regulatory 
role of estrogen - induced fluid absorption during the transfer of sperm in fluid from the 
testis through the efferent ductules to the epididymis (116).  Some pesticides such as 
DDT and many industrial chemicals have estrogenic or anti-estrogenic properties and 
may have deleterious effects on male and female health.  Declining sperm counts all 
around the world is regarded as a reflection of the adverse effects of estrogenic 
compounds on male fertility (236).    
 
Estrogen Receptors, Classical vs. Non-Classical Functions of Estrogen 
Many of the diverse biological effects of sex steroids are hypothesized to occur as 
follows: the hormone enters the cytoplasm by diffusion, translocates to the nucleus, 
interacts with nuclear receptor, and binds DNA resulting in transcriptional activation of 
steroid responsive genes.  The estrogen receptor (ER) when unattached to the ligand is 
loosely bound in the cytoplasm by a host of chaperone proteins.  These molecules 
function to stabilize the receptor in the inactivated state, prevent the receptor from 
binding to the DNA elements, and contribute to cross-talk among different signal 
pathways (249,260,270).  The exact location of the ER-chaperone complex is still 
uncertain.  The possibility is that there is an equilibrium distribution between the 
cytoplasm and the nucleus that could be shifted upon the stimulation with the estrogenic 
ligand.  When free estrogen diffuses into the cell, it binds with the ligand-binding domain 
of the ER.  The chaperones dissociate and estrogen-ER complex then migrates to the 
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nucleus and bind to specific sequences of DNA called estrogen response elements (ERE, 
5’GGTCAnnTGACC3’ where n=any nucleotide).  This DNA binding requires ER to be 
dimerized (287).  A host of ERE carrying genes has been defined (Table 1.1.2.1).  The 
estrogen-receptor complex not only binds to the EREs, but to co-activators or repressors 
thereby adding levels of regulation to the transcriptional activities of estrogen.  Estrogens 
also regulate the transcription of genes that lack functional EREs by interacting with 
other nuclear factors.  As an example, ER interacts with activating protein-1 (AP-1) 
subunits and modulates AP-1 dependent gene transcription (274).                        
Two types of nuclear ER, α and β which carry out estrogen-induced gene 
activation upon ligand binding have been demonstrated, depicting the classical steroidal 
hormone-receptor function.  However the effects of nuclear cofactors on ERα and β 
ligand binding and the correlation of ligand binding and gene transactivation have not 
been completely resolved yet.  Both isoforms are reported to originate from a single 
transcript and have near-identical affinities for E2 (225) though their tissue distribution 
and functional mechanisms seems to differ considerably.  ERα predominates in breast 
and uterine tissues (154) whereas ERβ is expressed in the central nervous system, 
endothelial cells and urogenital systems (Figure 1.1.2.2 (B)) (287).  Though both 
receptors share many structural similarities (Figure 1.1.2.2 (A)) their functional 
differences may add to the existing complexity of estrogenic effects.  The main difference 
between them lies within the AF-1 transactivation domain, which is inactive or even 
repressive in ERβ (109,154,296) in contrast to ERα whose AF-1 is active by itself.  
Interestingly both isoforms have virtually identical DNA binding domains suggesting that 
ERα and β interact with similar response elements.  Outcome and level of maintenance 
of activated signal cascades by both receptors differ in the presence of estrogen agonists 
and antagonists.  Several lines of human breast cancer cells and about 70% of breast 
cancers at initial diagnosis express estrogen receptors.   About 50% of these tumors are 
dependent on E2 for growth as evidenced by studies with anti estrogens (32,254).       
Estrogen and ER duet could yield to a magnitude of alternative pathways that may 
contribute to non-classical, non-genomic functions, some of which have been already 
described.  As for many other nuclear receptors, ligand independent activation of ER 
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Table 1.1.2.1
List of Putative Estrogen /ER Target Genes
Modified from Genome Biology 5:R66
Gene name Function
8
Proteolysis of the
receptor
D E
180 263 302 553 595
A/B C F
Dimerization, 
DNA binding
AF-2
Ligand dependent 
transactivation
function
AF-1
Ligand independent 
transactivation
function
148 214 304 500 530
15% 97% 30% 60% 17%
Ligand binding,
NLS,
dimerizationhinge
Human ERα
(A)
Human ERβ
Figure 1.1.2.2
Structure and tissue distribution of estrogen receptors (α and β)
(A) Structure of human estrogen receptors.  Function of various regions of the receptor 
are indicated in boxes. Numbers in red indicate position of amino acid residues.  
% indicates the percent homology between ERβ to ERα
(B) General distribution of both receptors in human
(B)
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(mostly ERα) has been reported.  ERs are members of the steroid hormone receptor 
family that are regulated by phosphorylation of tyrosine and serine residues.  Changes in 
the phosphorylation could invariably modulate their function.  Growth factors and other 
agents may possibly activate/inactivate these receptors through the activity of their 
downstream protein kinases.  Phosphorylated sites vary depending on the identity of the 
activated kinase/s, thereby adding more intricacies to the receptor function.  For an 
instance, PI-3 Kinase/Akt pathway phosphorylates ERα at consensus serine 167 
activating the receptor.  This activity confers protection against anti-estrogen therapy in 
breast cancer cells (43) possibly through blocking ER and anti-estrogen interaction.  
Similarly, resistance to tamoxifen was shown to be mediated by PKA through its target 
serine 305.  Upon phosphorylation of this site, ERα was unable to acquire the inhibitory 
conformation when bound to tamoxifen, and this led to growth stimulation in the 
presence of this anti-estrogen (191).  Additionally, serine 104, 106, 118 and 126 as well 
as tyrosine 357 have been identified as potential targets of various kinases and their 
phosphorylations appear to activate the receptor function.        
Although in vitro studies suggest the two species of ER may play redundant roles, 
a dissimilar tissue distribution indicates otherwise. Therefore the generation of mice 
lacking individual or both ER forms was a very effective tool.  Summary of reported 
phenotypes of ER null mice are shown in Table 1.1.2.2 (62).  ERα appears to be critical 
for the reproductive function in both male and female mice, where as ERβ holds an 
intermediary effect.  It is logical to argue that known genomic effects of estrogen are 
mostly mediated by the major isoform, ERα.  ERβ appears to show some redundancy in 
its function in certain tissues.  ERβ has been shown to posses opposing effects in 
response to estrogenic ligands (162), and may play a crucial role in maintaining a 
balanced state of estrogen effect on a particular tissue.  This information should be born 
in mind when interpreting data of knock out studies.  A single knock out may not 
necessarily provide the critical information regarding the particular ER; rather the effect 
may be the combination of that as well as the unchecked action of the other ER.     
The genomic mechanism of estrogen described above is unlikely to explain the 
rapid effects observed in target tissues such as bone, vasculature, neural, uterus and breast 
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Table 1.1.2.2
ER knock out model Phenotype
Lethality of mutation
ERα KO
ERβ KO
No
No
Fertility
ERα KO
ERβ KO
Both sexes are infertile
Female is subfertile (reduced litter size); males 
fertile 
General
ERα KO
ERβ KO
Exhibit normal expression of the ERb gene 
Exhibit normal expression of the ERa gene
Female reproductive tract
ERα KO
ERβ KO
Tract undergoes normal pre- and neonatal 
development but is insensitive to E2
Responsive to mitogenic actions of androgens 
Ovaries undergo normal pre- and neonatal 
development, but are anovulatory during adulthood, 
exhibit multiple hemorrhagic cysts, and no corpora 
lutea
30–40% incidence of ovarian tumors by 18 months 
of age 
Tract undergoes normal pre- and neonatal 
development and appears sensitive to ovarian 
estrogen cycling during adulthood 
Mammary gland
ERα KO
ERβ KO
Undergoes normal prenatal development but is 
insensitive to estrogen-induced development during 
puberty and adulthood 
Responsive to exogenous progesterone and 
prolactin
Undergoes normal prenatal and pubertal 
development, virgin gland is grossly 
indistinguishable from that of age-matched wild-
type 
Undergoes normal differentiation and lactation 
during pregnancy and motherhood 
(modified from Endocrine Reviews 20: 358-417) Phenotypes of ER Deficient Mice
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Table 1.1.2.2 continued
ER knock out model Phenotype
Male reproductive tract
ERα KO
ERβ KO
Tract undergoes normal pre- and neonatal 
development
Age-related phenotype of attenuated fluid
resorption in efferent ducts leads to dilation of 
Rete testis, atrophy of the seminiferous
epithelium, and decreasing sperm counts
Disrupted sperm function -inability to fertilize
Age-related decreases in testis weight 
Age-related increases in seminal vesicle weight
Undergoes normal pre- and neonatal 
development with no apparent defects in 
spermatogenesis that impede fertility
Cardiovascular system
ERα KO
reduced estradiol-induced angiogenesis 
and reduced basal levels of vascular nitric 
Oxide
Behavior – Females
ERα KO
ERβ KO
Exhibit a lack of estradiol and progesterone-induced 
sexual behavior, increased aggression, 
Exhibit no defects in sexual behavior that impede 
fertility
Behavior – Males
ERα KO
ERβ KO
Exhibit normal mounting and attraction toward
wild-type females but a complete lack of 
intromission and ejaculation; display reduced 
aggression
Exhibit no defects in sexual behavior that impede 
fertility
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tissue (214).  These effects do not fit into the time frame of classical genomic activity and 
suggest the existence of rapid, non-genomic activity.  Recent reports clearly show that E2 
is capable of activating kinase-regulated signal transduction pathways in MCF-7 and 
other cell lines (7,117,192,245).  Most of these studies further elaborate cell/tissue 
context specific estrogenic activities.  Further investigation into the estrogen signaling 
mechanisms has led to the hypothesis of cell surface estrogen receptors that could be 
coupled to cytosolic signal transduction pathways.  Membrane impermeable estrogens 
(E2-BSA) have been used to demonstrate possible membrane associated functions for 
decades.  Even though many signal cascades have been defined as response to these 
compounds, it is important to appreciate the inherent difficulties of the approach such as 
leakage of minute, undetectable levels of E2 that could signal the cellular responses.  
Expression of ER in cells lacking endogenous ER has been useful and it has 
tremendously helped to delineate signal networks associated with ER, yet it is not without 
setbacks.  Artificial expression of the molecule doesn’t always guarantee its optimum 
function.  Lack of factors that are indispensable for ER action (and present in naturally 
ER positive cells) could retard the receptor function in the new environment.  On the 
other hand, exogenously expressed ER may interact with host cell specific molecules 
producing unrelated effects.  Therefore information from this type of studies should be 
interpreted with caution.       
 Evidence for exclusively membrane bound ER in many cell types is slowly 
emerging.  Studies where overexpression of membrane anchored ERα was used to 
activate cytoplasmic signal transduction pathways (167) have attempted to explore the 
significance of membrane bound ER.  Consequently, the structural determinant that is 
necessary for the localization and function of ERα at the plasma membrane was 
determined (224).  Mutation of a specific serine phosphorylation residue (S522) to   
alanine significantly reduced the membrane localization of mouse ERα and the 
expression of this mutant in ER expressing cells abolished the binding of native ERα to 
the membrane.  Interestingly, the nuclear function of this mutant was comparable to that 
of wild type ER in response to E2.  Determination of the exact amounts of exclusively 
membrane bound and nuclear ER levels may pose difficulties since ER constantly shuttle 
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between the nucleus and the cytoplasm, despite its predominantly nuclear localization 
(195).  Based on microscopic evidence it is worth to speculate that the membrane pool of 
ERα represents a small proportion of the total immunoreacting receptors (189,195,224).  
Interpretation of data from ligand (estrogen) binding studies should also be done with 
caution since other estrogen binding entities that are not related to ER have been reported 
(275).               
In physiological condition the signaling mechanisms described above may operate 
as individual entities or may co-exist and interact.  The latter will add up to the existing 
complexity of our understanding in estrogenic effects.  Genomic, non-genomic, classical 
and non-classical activities of E2 and ER are demonstrated in the Figure 1.1.2.3.     
 
Estrogen and Breast Cancer  
Estrogen and the Development of Breast Tissue 
The fundamental feature of breast cancer is that it occurs far more frequently in women 
than in men, although men have breast tissue and sometimes get breast cancer.  Genetics, 
hormonal milieu and environment, all participate in the pathogenesis of breast cancer for 
a greater or lesser extent.  Presence of higher levels estrogen appears to act on the breast 
to make it susceptible for tumor formation in females.  In males, the plasma concentration 
and the production rate of estrogen are significantly lower than that in females (Figure 
1.1.2.4).  The inverse relationship is true for the level of testosterone in males and 
females.  This fundamental difference of hormone levels is the key to the distinct male 
and female physiologies.  Such differences could also make one gender more susceptible 
to specific disorders than the other.    
 Development of the breast tissue in female is a characteristically regulated by the 
action of estrogen (Figure 1.1.2.4).  Unlike the tissues that are fully formed at birth, 
breast tissue in newborns consists only of a small duct, which grows rapidly at puberty 
and completes full growth only after the first pregnancy (2).  The internal breast 
structures begin to expand rapidly under the influence of estrogen. Typically a girl's first 
period will begin about a year or two after her breasts begin to grow.  With every 
menstrual cycle a new phase of growth occurs which includes extensive branching of the 
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Modified from NEJM 346: 340-352Figure 1.1.2.3
Functional diversity of E2-ER
ER can be activated by 17-β-estradiol (E2) or independently of estrogen.  Growth factors 
indirectly activate ER by increasing  the activity of protein kinases which phosphorylate
sites on ER.  In the case of non-nuclear estrogen signaling pathway, cell membrane 
bound ER that may be found in caveolae, link their activity to mitogen activated protein 
kinase pathways.  This results in rapid nonnuclear effect.      
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(B) Average chronological sequence of hormonal and biological events in normal 
female puberty (modified from Physiology chap 55 pg1015)
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ductal system and organization of the internal structures.  The immature breast cells are 
inefficient in repairing gene mutations and more likely to bind carcinogens.  It is 
important to reduce the exposure of young women and girls to carcinogens that might 
damage DNA during the rapid phase of breast development.  After first full term 
pregnancy, a high proportion of breast cells are transformed to mature, differentiated cells 
that are less sensitive to DNA damaging agents.  Therefore susceptibility to mutations 
and resulting carcinogenesis may decline in the breast cells of women who have had an 
early full-term pregnancy (179).  Accordingly, increased risk of breast cancer in 
nulliparous women can be explained.  Similar level of risk has been observed in females 
who did not complete a full term pregnancy before the age of 30-35yrs.  This could be the 
direct result of the undifferentiated breast cells being exposed to carcinogens and DNA 
damaging agebts for an extended period of time.  If the cancer initiation process has 
already begun due to this reason, the full term pregnancy may not have a significant 
effect. 
 
Mechanisms of Estrogen Mediated Breast Cancer   
Diverse cellular and molecular mechanisms have been shown to mediate estrogen 
induced breast cancer progression.  Clinical and epidemiological data have led to the 
conclusion that endogenous E2 has a critical role in sporadic breast cancer in women.  
Two enzyme systems compete for an opportunity to alter the structure of E2 molecules, 
but they do so at two different locations, the 2- and 16-carbon positions (Figure 1.1.2.1).  
The end products of such reactions are quite different in their biologic roles.  Insertion of 
a hydroxyl radical at the 2-carbon site produces a neutral molecule while that at the 16-
carbon location produces a genotoxic molecule, which increases the chances of 
spontaneous mutation (269).   
Endogenous and exogenous estrogens may initiate and promote breast cancer via 
two key mechanisms in susceptible individuals.  First, estrogen may also contribute to 
mammary carcinogenesis by stimulating the proliferation of a clone of precancerous 
cells.  There is evidence that estrogen decreases cell cycle transit time, so that DNA 
damages and mutations could be passed to the daughter cells before repair (51) perhaps 
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due to defective DNA damage checkpoint functions.  Cell cycle effects of estrogen have 
been studied extensively.  These studies show that mitogenic abilities of estrogen are 
mostly mediated by genomic functions of estrogen.  Estrogen-ER complex induces DNA 
synthesis, cell division and production of biologically active proteins such as pS2, 
transforming growth factor (TGF), and epidermal growth factor (EGF) that induce cell 
growth and differentiation (4).  In breast cancer xenograft models using ER positive cell 
types, E2 produced pre-malignant and malignant lesions at high frequency compared to 
untreated samples (239).   
Second, estrogen prevents cell death, especially apoptosis through ER (226), 
mitogen activated protein kinase (MAPK) (251), phosphoinositide 3-kinase (PI-3K) (261) 
mediated pathways in cell cultures.  Data in this dissertation demonstrate the significance 
of these types of cell signal pathways in estrogen-induced anti-apoptosis, in response to a 
variety of stimuli.  Estrogen acts in synergism with anti-apoptotic proteins such as BCL2 
(57,210) while abolishing the effects of pro-apoptotic molecules (129 and data in 
dissertation).  The mitogenic and survival promoting effects of estrogen are further 
confirmed by observations that the anti-estrogens or estrogen withdrawal can either block 
breast cancer cell proliferation or induce apoptosis (129 and data in the dissertation).  In 
clinical setting, traditional hormonal therapy for women with breast cancer included 
hormone ablation by surgical procedures (oophorectomy, adrenalectomy).  Later on, anti-
estrogens and aromatase inhibitors superseded this strategy (218).  Paradoxically, 
hormonal therapy with high estrogen doses caused regression of ER positive breast 
cancer in post-menopausal women (142).  This response was shown to directly correlate 
with the duration of the post-menopausal period.  This clinical data may suggest that 
long-term exposure to very low levels of estrogen might alter the responsiveness of breast 
cancer to estrogen therapy.  Similar phenomenon was later shown in cell culture systems 
using long-term estrogen deprived (LTED) MCF-7 cell variety.  Further estrogen induced 
apoptosis in these cells when administered in higher doses (252).  These observations 
clearly provide a clue that the adaptation of cancer cells to lower blood levels of estrogen 
might sensitize them to pro-apoptotic effects of estrogen.  To extend the breast cancer 
treatment in pre- and post-menopausal women, a new regimen of cyclic treatment 
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strategies would need to be introduced.  Here selective estroigen recptor modulators 
(SERMs) or aromatase inhibitors can be used for period of time to sensitize the cancer 
cells to apoptotic effects of estrogen (253)         
 
Environmental Estrogenic Compounds and Breast Cancer  
In biological regulatory pathways, molecules compete for their receptors.  Such 
competition among molecules is based upon their structural similarities.  However, many 
synthetic chemicals not belonging to the family of human hormones actively compete for 
receptors for that family.  This natural phenomenon is well illustrated by the example of 
competition for receptors among estrogens and estrogen mimics such as, pesticides (DDT 
and heptachlor), plastic (polycarbonates) breakdown products, PAHs (polycyclic 
aromatic hydrocarbons), petroleum byproducts, polystyrene, plant estrogens such as 
coumestrol, equol and zearalenone.  It has been suggested that these xenoestrogen 
molecules may have 3D structures that can fit in the ligand binding site in the steroid 
hormone receptor.  Therefore, the total burden of estrogen in an individual is constituted 
of endogenous and exogenous estrogens.  Exposure of previously unexposed women to 
xenoestrogens in addition to dietary changes may be partly responsible for higher rates of 
breast cancer in oriental females who migrate to the United States.  In susceptible 
individuals, it is possible that environmental carcinogens and estrogenic compounds 
might synergistically enhance the development of breast cancer (78,128,233). 
 
Estrogen Action on Tumor Vascularization  
In both tumor growth and metastasis, angiogenesis plays an essential role.  Growth 
factors, cytokines and extra cellular matrix have been shown to regulate endothelial 
function in vivo and in vitro (239).  Estrogen action in endothelial cell function also has 
been appreciated pertaining to its cardiovascular activities (13).  The evidence shows that 
estrogen guards against cardiovascular diseases in reproductive years and the protection 
wanes as women reach menopause (21,40).  Mechanism/s of estrogen function in 
vascular component of breast cancer has been proposed, thus estrogen was shown to 
increase the expression of vascular endothelial growth factor (VEGF) and other 
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angiogenic factors in breast cancer cells (156,290).  Paradoxically, E2 inhibited the 
growth of breast cancer xenografts (of KPL-1 cells) in nude female mice by abolishing 
angiogenesis as well as the level of VEGF production, and the anti-estrogen ICI 182, 780 
had opposing effects (156).  Whether these cells are ER positive or negative was not 
defined.  On the other hand, high levels of ER have been shown to inhibit proliferative, 
invasive and metastatic potential of a subset of tumor cells in vitro (11).  Subsequent to 
ERα overexpression, in vivo down-regulation of VEGF and inhibition of vascularization 
was observed in tumor xenografts. 
  
Selective Estrogen Receptor Modulators (SERMs)   
Receptor mediated estrogenic functions are further modulated by a host of co-regulator 
proteins, and the complex nature of these interactions may impart distinctive effects in 
different target tissues.  Estrogen has multiple desirable effects such as improved bone 
density, lipid profile, and benefits for the cardiovascular and central nervous systems.  
Unfortunately there are undesired effects including increased breast cancer risk, 
stimulation of endometrial hyperplasia and increased risk of venous thrombo-embolism 
(VTE).  Estrogenic compounds that block or antagonize the effects of estrogen in specific 
tissues while retaining some of the beneficial effects in other tissues have shown great 
benefits in post-menopausal women as well as women who undergo ovariectomy early in 
the life.  These pharmacological agents, known as selective estrogen receptor modulators 
(SERM) are mainstays in treatment of metastatic breast cancer and have shown promise 
as chemo-preventive agents for breast cancer and osteoporosis.  SERMs function by 
competing for the ER binding to estrogen.  Subsequent to ER-SERM interaction, 
conformational changes occur in ER thereby blocking ER mediated effects (190).  
SERMs posses varying degree of estrogenicity (complete or partial, agonists or 
antagonists) depending on the target tissue.  This tissue selectivity is well demonstrated 
with Tamoxifen, an anti-estrogen used in breast cancer therapy.   The rationale for its use 
is based on the fact that E2 is a mitogen in ER-expressing breast cancer cells and, this 
action can be inhibited by an ER antagonist.  Clinical data demonstrated that Tamoxifen 
abolished ER dependent breast cancer and promoted increase in bone mineral density 
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mimicking the estrogen effect in this tissue (136) as well as in the uterus (124).   Receptor 
sub-type difference in ER could also influence the pharmacological effects of SERM.  It 
has been shown that almost all SERMs have antagonistic effect on ERβ where as more 
differential effects are seen on ERα (190).  Therefore it is possible that differential 
expression of ERs could at least partly contribute to the tissue selective effects of SERM.  
Structures of some SERMs and their mode of action are shown in Figure 1.1.2.5.   
 
Aromatase Inhibitors 
Another approach to anti-estrogen therapy is to lower the amount of estrogen being 
produced by the body.  In post-menopausal women, estrogen is no longer produced by 
the ovaries, but is synthesized from testosterone in the peripheral tissues by a reaction 
catalyzed by the enzyme aromatase (40).  Aromatase inhibitors block testosterone from 
being converted to estrogen thereby limiting the available estrogen level.  Recent studies 
using third generation aromatase inhibitors (anastrozole, letrozole and exemestane) have 
shown better outcome and improved therapeutic ratio over hormonal approaches 
(progestins) and over Tamoxifen. These results have led recently to testing of aromatase 
inhibitors in the adjuvant setting for postmenopausal patients (218,268).     
 
1.1.3 Apoptosis 
Different Ways to Die 
Cell proliferation and growth are among the most intensely investigated areas in the field 
of cancer research.  The notion that programmed cell death (PCD) plays a major role in 
the life of multi-cellular organism has gained attention recently and convincing evidence 
is accumulating at a fast rate.   When a cell of a multi-cellular organism dies by a 
mechanism exerted by proteins encoded by the host’s genome, the process can be defined 
as physiological cell death.  The purpose of this process is to eliminate unwanted host 
cells and is important in development and homeostasis, as a defense mechanism and as a 
final stage of the aging process.  Most genetic or non-genetic changes that deregulate 
these cell death programs may underlie the etiology of cancer, autoimmune and 
developmental disorders.   
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(B)
Modified from 
NEJM 346: 340-352
Figure 1.1.2.5
(A) Structures of SERMs.  The structure of estradiol is also shown for comparison 
(B) Estrogen binding promotes ER comformational change that permits its spontaneous 
dimerization and facilitates the subsequent interaction of the dimer with EREs located within 
target genes.  Estrogen also facilitates the interaction of the ER with coactivators.  An 
antagonist-activated ER, on the other hand, interacts preferentially with a corepressor protein.  
Evidence suggests that the structure of some SERM–ER complexes favors corepressor
recruitment and that of others favors affinity for known coactivators.  The implication of 
this model is that SERM activity will be influenced by the relative levels of expression of the 
cofactors (corepressors and coactivators) in target cells.
Modified from Science 29:2380-2381
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The term ‘apoptosis’ has been used interchangeably with PCD and has immensely 
confused the understanding of regulated cell death.  Activation of caspases (aspartate 
directed cystein proteases) is the final commitment step to apoptosis in a normal cell (39).  
Function of caspases is conserved throughout evolution from nematodes to mammals.  In 
mammals the process is considerably more complex involving multiple forms of caspases 
and their targets.  Resulting cell death is characterized by unique morphological features 
(described below).  Other forms of cell death, which are morphologically and 
mechanistically distinct to apoptosis could exist and some of them have been described 
(178,255).  It may now be the time to note that caspases are not the sole or unique 
effectors of cell death programs.  In fact, the inhibition of caspases does not prevent the 
total cell loss due to apoptotic stimuli (14) or in severely compromised cells by growth 
factor withdrawal, metabolic toxins or physiological killers like glucocorticoids (178).  
Interestingly, organisms that do not express caspases undergo PCD that does not closely 
resemble classical apoptosis (17,91,161,177).  Together it is now evident that there are 
multiple pathways leading to cell death.  Some cells may have the required components 
for some pathways but not for others.  Also cells may contain inhibitory mechanisms that 
rule out a particular program.  Moreover, different pathways can co-exist in the same cell 
and are switched on by specific stimuli.   
 
Apoptosis 
For a tumor biologist defective apoptosis is one of the seven pillars upon which cancer 
develops and progresses.  Defective cell cycle regulation, growth factor autonomy, 
defective senescence, angiogenesis, metastasis and cell invasion are the other six pillars 
(73).  Apoptosis is a genetically encoded and highly regulated cellular response for a pro-
death signal.  This results in unique characteristic features such as cytoplasmic shrinkage, 
membrane blebbing, nuclear fragmentation, intranucleosomal DNA fragmentation, 
phosphatidylserine exposure due to changes in the plasma membrane, and finally 
fragmentation into membrane enclosed apoptotic bodies sequestered by macrophages or 
other engulfing cells or neighbors (73,143,291).   
 
23
Mechanism of Apoptosis 
When discussing the central components of apoptosis, it is most appropriate to describe 
C. elegans’s genes whose functions led to the discovery of higher eukaryotic 
homologues.  The core machinery of apoptosis was first discovered in C. elegans and 
include Egl-1, Ced-3, Ced-4 and Ced-9 whose mammalian homologues are BH3-only 
proteins, caspases, Apaf-1 and BCL2-like proteins respectively (39).  The process in the 
higher mammals is more complicated than in the worm though the basic makeup of the 
mechanism is comparable.  Activation of caspases is responsible for the cleavage of vital 
components of the cell and it is during this process the characteristic morphological 
features of apoptosis (described above) are produced (39).   
Major form of apoptosis in vertebrates is mediated by the mitochondria associated 
mechanism (102).  Caspases are commonly activated by mitochondrial membrane 
permeabilization (MMP), or more specifically mitochondrial outer membrane 
permeabilization (MOMP) (103), which marks a point of no return from the death 
process.   MMP leads to the release of proteins normally found in the space between the 
inner and outer mitochondrial membranes, such as cytochorme C and apoptosis inducing 
factor (AIF) to the cytosol.  Though the exact mechanism of MMP is still being debated, 
it is clear that local effects on inner and outer mitochondrial membranes could lead to 
differences in the membrane potentials.  Defective inner transmembrane potential (∆Ψm) 
has been clearly observed before, during and after MMP (104).  The mitochondrial 
respiratory chain produces energy which is stored as an electrochemical gradient or the 
∆Ψm, negative inside of about 180-200 mV.  This energy source pumps protons (H+) that 
drive ATP synthesis.  Loss of ∆Ψm is a result of the ion equilibration across the inner 
membrane.  This could lead to swelling of the matrix as water enters, which can result in 
sufficient swelling to break the outer membrane to produce MMP.  MMP contributes to 
cell death in several different ways.  In apoptosis by releasing cytochrome-C, in caspase 
independent cell death by releasing factors like AIF (262) and Htra2/Omi (114) and, by 
culminating mitochondrial functions that are essential for cell survival such as electron 
transport chain (101).  Once in the cytosol, cytochrome C contributes to the formation of 
the apoptosome (Apaf-1/caspase 9/cytochrome-C) that activates the executer caspases 
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(39).  A pathophysiological role for MMP is emerging and manifestations of deranged 
∆Ψm and release of intermembrane proteins are frequently observed in diseases with 
increased cell death (104).                   
In addition to the mitochondrial-mediated pathway, ligand binding and activation 
of the cell surface death receptors has also been implicated in activating caspases.  
Activated receptors initiate the recruitment of pro-caspases (eg. pro-caspase 8) and their 
adaptor molecules to form the caspase processing unit.  This aggregation results in the 
transactivation of pro-caspases and consequent cleavage and activation of the down 
stream capases and other targets.  A cascade of biochemical reactions follows, ensuring 
the final fate of the cell.  The cell surface receptor cascade also contributes to the 
mitochondrial cytochrome – C release through the activation of caspase 8 and its down 
stream target BID (39).  Finally both mechanisms converge into cleavage and activation 
of Caspases 3, 6 and 7 which carry out the proteolysis of death substrates (Figure 
1.1.3.1).  These pathways are tightly regulated by pro and anti- apoptotic mechanisms 
and the balance between them may govern the orderly demise of the cell.     
 
Caspases 
Caspases are a well-characterized family of cysteine proteases that are responsible for the 
execution of apoptosis.  They are also important in other cleavage dependent functions 
such as cytokine maturation (10).  As the name implies (‘c’ is for cysteine and ‘aspase’ is 
for aspartate) these enzymes are able to cleave the substrate after an aspartic acid residue.  
Each caspase is initially synthesized as a pro-caspase and requires a cleavage at specific 
site (which also is an aspartate) by another caspase to generate active enzyme suggesting 
a cascade activity of this family of proteases.  Functional apoptotic program in mammals 
requires multiple caspases and the contribution of different caspases to different phases of 
apoptosis is becoming clearer (39).  Currently, 11 human caspases have been identified: 
caspase 1-10 and caspase 14.  The protein initially named caspase 13 was found to be the 
bovine homologue of caspase 4.  Caspase 11 and 12 are murine homologues of human 
caspase 4 and 5 (73).  Caspases are classified in several ways.  Most important of those is 
the function-based classification where all caspases are fit into three subfamilies i.e. 
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General overview of apoptosis
See text for details
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initiators of apoptosis and inflammation (caspase 1, 5, 11), initiators of apoptosis 
(caspase 2, 8, 9, 10, 12) and effectors /executors of apoptosis (caspase 3, 6, 7) (73).    
Caspases posses very strict substrate specificity.  Target substrates can be 
subdivided based on their cellular functions i.e. (a) proteins directly involved in 
regulation of apoptosis, (b) protein kinases that mediate apoptosis, (c) structural proteins, 
(d) proteins required for cellular repair, (e) cell cycle regulatory proteins and (f) proteins 
involved in diseases.  These are summarized in Table 1.1.3.1 (73).   Mouse knock out 
studies have contributed enormously to the current knowledge on specific roles of 
individual caspases.  Phenotypic details of these mice are shown in Table 1.1.3.2..                                    
                                                                                                                                                                        
Regulation of Caspase Activity and Apoptosis 
Regulation of caspase activity is implicated in apoptosis and to a lesser extent in cell 
proliferation and cellular differentiation.  In the latter, limited activation of caspase has 
been demonstrated to be essential i.e. proliferation of lymphocytes (8), differentiation of 
red blood cells (35) and epidermal cells (87).  A family of proteins termed ‘inhibitors of 
apoptosis’ (IAP) has been described to play a major role in caspase regulation hence 
apoptosis regulation.  These proteins function as intrinsic regulators of the caspase 
cascade.  There are other cellular proteins that modify specific caspases, but IAPs are the 
only proteins that can regulate initiator as well as executor caspases.   
Several IAPs have been described to date e.g. the first mammalian homologue 
neuronal IAP (NIAP), X-chromosome linked IAP (XIAP), Survivin and Livin.  They are 
characterized by the presence of one or more of baculoviral IAP repeats (BIR).  This 
domain is important in binding and inactivation of caspases (173).   In addition to 
apoptosis regulation these proteins have been shown to participate in cell cycle regulation 
and receptor mediated cell signaling.  Both endogenous (mitochondria mediated) and 
exogenous (surface receptor mediated) apoptosis pathways are regulated by IAPs.   
Regulatory proteins that bind and suppress the function of IAPs have been 
described.  Mitochondrial protein Smac, which is released by a similar mechanism as 
cyctochrome-C, has been shown to bind to all the IAPs.  In addition to Smac, other 
mitochondrial and cytoplamic IAP inhibitors have been shown to regulate IAP function.   
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Table 1.1.3.1
 List of some caspase substrates 
Modified from Oncogene 22: 8543
Apoptotic and inflammatory regulators
BID, Caspases, BCL2, BCLxl, XIAP, IkB, 
Protein kinases and other signal molecules
Raf, AKT, PP2A, MEKK1, PKC, FAK
Structural proteins
Actin, Lamin A-C, β-catenin,  
Repair proteins
PARP, ATM, DNA-PK, Rad51, Rad9
Cell cycle regulators
Rb, p27, p21, Cdc27
Disease related proteins
Huntingtin, ataxin-3, androgen receptor, atropin
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Table 1.1.3.2
Summary of phenotypic characteristics of caspase knockout mice
Modified from Oncogene 22: 8543
Caspase
Embryonic 
lethality 
Developmental 
defects
Apoptotic defects
1 No No Defects in inflammatory response
Resistance to septic shock
11 No No Defects in lymphocyte apoptosis
Resistance to septic shock
Ischemic brain injury
2 No Excessive oocyte
generation 
Defects in apoptosis induction in oocytes
and lymphocytes 
Compensatory activation of other 
caspases were reported 
3 Yes Neuronal hyperplasia Defects in DNA fragmentation 
Compensatory activation of other 
caspases were reported
8 Yes Impaired cardiac 
muscle formation
Abdominal bleeding
Defects in activation of death receptor 
pathway
9 Yes Neuronal hyperplasia Defects in apoptosis induction by 
genotoxic stress
12 No No Defects in endoplasmic reticulum stress 
apoptosis
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IAPs can also be substrate targets of caspases, showing another level of apoptosis 
regulation.  In some instances such cleavage yields a pro-apoptotic molecule that 
accelerates the death process where as in other instances it simply represents the final 
outcome of apoptosis (76,173).     
 
Endoplasmic Reticulum and Apoptosis 
Critical contribution of endoplasmic reticulum (End.Ret.) to apoptosis has been evaluated 
recently.  The End.Ret. induces stress signaling in response to defective protein folding 
through the unfold protein response (UPR) that ultimately drives cell to apoptosis (15).  
This phenomenon if termed as ER-stress induced apoptosis.  The mechanism by which 
ER-stress is coupled to caspase activation was revealed by the characterization of caspase 
12 (198).  Caspase 12 is specific in its function for ER-stress as has been demonstrated by 
null mouse studies (Table 1.1.3.2).  In addition to the direct activation of caspase 12, 
End.Ret. acts in concert with mitochondria to propagate apoptotic signals.  This has been 
shown to take place through several pathways.   Increased cellular concentration of Ca2+ 
is frequently observed with End.Ret. stress.  This can potentially activate Ca2+ dependent 
enzymes such as calcineurin whose down stream effector is the BCL2 family protein 
BAD.  BAD is dephoshorylated (activated) by this enzyme thereby promoting the 
mitochondrial action of BAD (282).  Further, increased Ca2+ was shown to directly 
activate mitochondrial mediated cytochrome-C release (15).  Multi-domain BCL2 family 
proteins (pro- as well as anti-apoptotic) have been shown to localize to the ER membrane 
(148,153).  As in mitochondria, pro-apoptotic BAX like proteins inflict membrane 
damage that can be prevented by the expression of BCL2 group.  Changes in End.Ret. 
membrane cause changes in Ca2+ mobilization that may contribute to the apoptotic 
program as described above.  Correct protein folding is essential to maintain the 
homeostasis of the cell.  the End.Ret. acts as the sensor for this mechanism and stops the 
metabolic processes until the defect is corrected.  It is when the protein folding capacity 
of ER is compromised due to a variety of reasons the UPR mediated signal directs the 
apoptotic program.  It is likely that various apoptotic agents described thus far may also 
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have effects on ER.  The outcome could then be due to all these programs that work 
simultaneously.       
 
BCL2 Family Members and Apoptosis  
Apoptosis is highly conserved in multicellular organisms and information gathered from 
studying less complex species have been easily translated to more complex counterparts.  
Identification of remarkable similarity between the C. elegans ced-9 gene members and 
mammalian BCL2 family is the best case in point (5).  Several proteins have been 
identified to be members of the family subsequent to the discovery of the founder 
member, BCL2.  BCL2 was described in 1988 as a protein, which is involved in B-cell 
lymphomas (277). BCL2 transfected B cells were shown to be resistant towards apoptosis 
normally induced in B cells by IL-3 withdrawal: for the first time it was shown that the 
pathway toward tumorigenesis depends not only on the ability to escape growth control 
but also on the ability to prevent apoptosis.  Interestingly, expression of human BCL2 in 
C. elegans reduced the amount of programmed cell death suggesting that the mechanism 
controlled by BCL2 in human is similar to that in nematodes (278).  
 
Structure and Function of BCL2 Proteins 
A hallmark of BCL2 family members is to form hetero or homo dimers, which may 
either, be a competition for neutralizing or, result in a synergetic effect.  Possession of 
one or more of conserved BCL2 homology (BH, 1-4) domains determines the structural 
and functional capacities of each member.  BCL2 and BAX subfamilies that contain BH 
1-3 (Figure 1.1.3.2) show opposing anti-apoptotic and pro-apoptotic effects respectively.  
BH3 only proteins compose the third family, which is strictly pro-apoptotic.  They may 
directly counteract the activities of anti- apoptotic members or induce death via 
alternative mechanisms (61,106).  However it is clear that their apoptotic function is 
solely dependent on the presence of BAX subfamily members (301).  At the C-terminus 
of most BCL2 and BAX and in certain BH3 only proteins is a hydrophobic region, which 
features as a trans-membrane domain important for their membrane targeting (61).  
Despite the structural similarities, BCL2 proteins differ in their subcellular localization.  
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Figure 1.1.3.2
BCL-2 family members
BCL-2 homology regions (BH1-4) are denoted as is the carboxy-terminal hydrophobic 
trans-membrane (TM) domain
Modified from  Genes and Dev 13: 1899-1911  
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Among the anti-apoptotic members, BCL2 and BCLxl are found extensively membrane 
bound in mitochondrial and ER fractions while BCLw is mainly cytosolic.  In the pro-
apoptotic group, BAK is mostly membrane bound and BAX is cytosolic (61).  Recent 
structural studies have provided insights regarding these differences.  In BAX and BCLw, 
the C-terminal regions were shown to interact with the groove made up of BH1/2/3 and 
therefore, unavailable to interact with membranes (118).  The hydrophobic groove is the 
target for the BH3 domain of the binding partner and, then there is a need for a 
competitive displacement of the C-terminal from the groove.  Since BCL2 and BCLxl are 
mostly bound to the membrane through the C-terminal transmembrane domain, it is 
presumed that their hydrophobic groove is available to bind with interacting BH3 
domains.   
 Pro-apoptotic BAX family members are critical for apoptosis in many cell types.  
Double knockouts of these genes have deleterious effects and results in prenatal death, 
where as single knockouts show little consequence (170) probably due to functional 
redundancy.  Upon apoptotic signal, BAX and BAK undergo conformational changes and 
form homo-oligomers (193,200).  This may require the rearrangement of their BH 
domains so that one molecule may act as the donor of the BH3 domain and the other as 
the acceptor (the hydrophobic groove).  Once activated, BAX and BAK cause membrane 
damage, particularly the outer membrane of the mitochondria (influence MMP, described 
above).  BCL2 and BCLxl over-expression has been shown to neutralize the effects of 
BAX and BAK (113,256).   
Individual BH3 only proteins appear to have direct and indirect effects on pro-
apoptotic BAX family proteins, contributing to apoptosis induction.  BID, upon cleavage 
in response to cytotoxicity binds and directly activate BAX (165,169).  BAD and BIK 
cannot directly activate BAX or BAK but instead binds anti-apoptotic BCL2 preventing 
their functions (5,22,165).  This information supports the view of two modes of action for 
BH3 domains i.e. (1) activating BAX, BAK and (2) sensitizing by occupying the pocket 
of anti-apoptotic members.  Table 1.1.3.3 summarizes the known functions of some 
BCL2 family members.            
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Family member Functions
BH3 only
BAD Knockout mice develop normally, with time 
display diffuse large B cell lymphoma.
BID Knockout mice develop myeloproliferative
disorder.  Hepatocytes are resistance to Fas
mediated apoptosis.  
Noxa Induced by p53.  MEFs are resistant to DNA 
damage induced apoptosis when Noxa is 
knocked out.  
BIM and BOD Knockout mice show increased lymphoid cells.  
Anti-apoptotic
BCL2 Deficient mice have defects in renal
development, loss of lymphocytes, 
melanocytes and hair  pigmentation.  
Effects are reversed by BIM deficiency
BCLxl Knock-out is embryonic lethal. 
Massive increase in apoptosis in erythroid and 
neuronal cells
BCLw Deficient mice are viable.  Males are impotent
Mcl Knock-out is embryonic lethal
Pro-apoptotic
(multidomain)
BAX Deficient mice are viable.  Lymphocyte 
number is Increased  
BAK Develop normally
BAX/BAK double knockouts die perinatally
due to various developmental defects.  Absence 
of MMP
Table 1.1.3.3
Summary of  functions BCL2 family members Modified from Science 305: 626-629,Cell 75: 229, Nat.Gen 16: 358) 
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BCL2 family proteins have been shown to participate in other cellular functions in 
addition to apoptosis.  Cell cycle transit from quiescence to proliferation was blocked 
when BCL2 proteins were over-expressed (64) but high levels of BCL2 did not affect the 
proliferating rate of continuously growing cultures (61).  Most importantly the anti-
apoptotic and cell cycle effects of BCL2 appear to be genetically separable i.e. cell cycle 
effect depends on the amino terminal BH4 domain (121,127).  BAD was also shown to 
exert a cell cycle effect.  BAD expression resulted in failure to block cell cycle 
progression in fibroblasts following release from growth arrest conditions.  Using 
mutation analysis it was shown that BAD requires co-segregation with BCL-xl to exert 
this effect (50).  Contrary to this, data in this dissertation show that BAD over-expression 
blocks cell cycle progression in breast cancer epithelial cells in growth arrest as well as 
continuously growing conditions.  Further we demonstrate that endogenous BAD has a 
regulatory role in cell cycle progression at the level of cyclin D1 transcription.                  
The BCL2 family proteins are frequent targets of post-translational modification 
downstream of both survival and death signal transduction cascades and such 
modifications may often dictate their active versus inactive conformation, sub-cellular 
localization, and partner proteins (5).  The ratio between pro and anti-apoptotic members 
helps to determine at least in part the susceptibility to a death signal (140,301).   
 
BAD 
BAD (BCL-/BCLxl Associated Death promoter) is an exclusively BH3 domain only 
member sharing sequence homology only within the BH3 amphipathic α-helical domain 
(Figure 1.1.3.2) in the BCL2 family.  It was originally cloned from mouse cDNA by its 
ability to bind with BCL2, both in yeast two-hybrid and direct biochemical interactions 
(294).  Subsequently the human homologue, which is 37 amino acids shorter, was 
identified.  Both mouse and human counterparts are expressed ubiquitously.  BAD 
promotes cell death; and it is widely accepted as a pro-apoptotic protein.  As for any 
other pro-apoptotic BCL2 member (i.e. BID, BIK, BAK and BAX) intact BH3 domain is 
important for BAD’s function.  It competes for the binding with BCLxl and BCL2 to a 
lesser extent, via the BH3 domain thereby affecting the level of heterodimerization of 
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these proteins with BAX or BAK (119,140,204).  Possible interactions among BCL2 
family members are shown in Figure 1.1.3.3.    
 
Inactivation of BAD 
Phosphorylation of BAD on several serine sites found in and out of the BH3 domain 
change the effectiveness of BAD as a death-promoting molecule.  In the presence of most 
survival factors, cells phosphorylate BAD on serine 75 (murine S112) by Ras mediated 
ERK/RSK1 pathway (90).  Subsequent phosphorylation on serine 99 (murine S136) by 
protein kinase B/AKT (70) promotes heterodimerization with 14-3-3 proteins.  Such 
interaction then facilitates the phosphorylation at serine 118 (murine S155) a site within 
the BH3 domain, by PKA (175).  Phosphorylation in the BH3 domain weakens the 
interaction with BCLxl thereby leading to the cell survival (22,82,119).  
Recently another inactivating phosphorylation site, serine 133 (murine S170) 
outside the BH3 domain was shown to be important in cytokine induced cell survival 
(83), although it remains uncertain which kinase/s is responsible for the phosphorylation.  
Deletion of the BH3 domain was shown to completely abolish the pro-apoptotic function 
of BAD (140) whereas, point mutations within this domain (leucine 114, aspartate 119; 
murine L151 and D156 respectively) have not established any significant corelation with 
BAD’s functions (personal communication Dr. A. Kelekar), (3).   
 
Activation of BAD 
BAD can also be activated by phosphorylation in response to death signals.  To this end 
serine 91 (murine S128) has been shown as critical target for phosphorylation by stress 
activated JNK signaling pathway.  Interestingly the activity of growth factor mediated 
signaling failed to inhibit apoptosis induced by BAD S91 phosphorylation, depicting 
opposing signaling mechanisms that converge on BAD (80).   
Reversible phosphorylation is a key regulatory mechanism in cell survival and 
death, and has been shown to regulate the function of BAD.  Members of major 
eukaryotic serine/threonine phosphatase families have been discovered to de-
phosphorylate BAD, even though conflicting data for their specificities are obvious.  
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Figure 1.1.3.3
Interactions among BCL2 family proteins
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BAD is a target for Ras activated phoshatase (PP1α) as well as calcineurin (PP2B) in 
Ca2+ induced apoptosis (19,247).  14-3-3 was shown to actively protect BAD against de-
phosphorylation by PP2A in vitro implicating that 14-3-3 holds a regulatory role in BAD 
de-phosphorylation (55).  On the other hand, BCL2 targets BAD for de-phosphorylation 
by PP1α.  BCL2 possesses the consensus sequence (RIVAF) important for PP1α 
interaction and contributes to the formation of a trimolecular complex thereby facilitating 
the dephosphoryaltion of BAD by PP1α  (20).  These mechanisms depict the existence of 
regulatory processes that ensure latent status of BAD, which is constitutively expressed 
in normal cells.   
BAD has been shown to undergo cleavage by caspase 3 resulting in a more potent 
pro-apoptotic molecule.  This phenomenon was observed in apoptosis caused by 
interleukine (IL3) deprivation in murine myeloid precursor cells (59) and in response to 
Raloxifene (mixed estrogen agonist/antagonist) in human bladder cell line (147).  
Whether BAD is cleaved by proteases other than caspase 3 is not yet clear.  In cells that 
do not express caspase 3 (e.g. MCF-7 (131)) BAD might not be effectively cleaved.  
Notably, in the studies with MCF-7 we have not observed cleaved form/s of BAD in 
response to the host of apoptotic stimuli that were used.  Several other BCL2 members 
are also targets for proteases thus showing that cleavage is another post-translational 
modification of this family of proteins.  Pro-apoptotic BID undergoes cleavage by 
caspase 8 and by granzyme B and promotes mitochondrial release of cytochrome C 
(169).  In some circumstances anti-apoptotic BCL2 and BCLxl were shown to undergo 
cleavage thus forming potent pro-apoptotic molecules (54,58).              
The cellular location of BAD is considered to be cytoplasmic since it is devoid of 
the membrane anchoring hydrophobic region, which is present in most other BCL2 
family members (Figure 1.1.3.2).  Upon its interaction with BCLxl or BCL2 that are 
anchored onto the mitochondria BAD may be found in the mitochondria.  Active survival 
mechanisms inflict inhibitory phosphorylation of BAD and promote sequestration of 
BAD away from mitochondria.  Whether BAD, either phosphorylated or not, has cellular 
locations other than the cytoplasm and mitochondria is currently unknown.  The 
important phosphorylatable residues and domains of BAD are shown in Figure 1.1.3.4.    
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Information on phosphorylation of BAD may not be sufficient to explain its role in cell 
survival/death process.  The large number of signaling pathways that target BAD is 
perhaps surprising, but there are indications that more may be discovered soon.                       
Recently transgenic mouse studies showed that survival factors are less protective 
against insults when BAD gene is knocked out.  Moreover, the knocked-in 
unphosphorylatable BAD did not increase cell death, yet increased the animal’ s 
susceptibility for carcinogens, highlighting the impact of BAD phosphorylation on three 
serine residues (75, 99 and 118 (murine 112, 136 and 155 respectively) (71,222)).  These 
studies concluded that BAD is a sensitizing intermediate through which survival factors 
set the threshold for apoptosis.   
 
Apoptosis and Beast Cancer 
In an adult woman, the cell death in the form of apoptosis and cell proliferation are the 
key determinants of the mammary gland homeostasis (155).  During the menstrual cycle 
apoptosis occurs at varying rates in response to changes in hormone levels in the breast 
tissue (220) as well as in the endometrium (66).  Similarly, apoptosis plays a key role in 
the post-lactational involution subsequent to pregnancy (134).  Apoptosis is also 
regulated by non-hormonal signals.  Changes in apoptotic regulatory mechanisms due to 
genetic abnormalities may results in increased cell number, promoting tumor 
development and progression.  This could promote metastasis by enabling the tumor cells 
to survive in the circulation and grow in distant places.  Upon detachment from the 
basement membrane, epithelial cells undergo apoptosis, which is defined by the term 
anoikis (96).  In order to metastasize, breast carcinoma cells should overcome anoikis.  
Proliferation and apoptosis also determine the growth dynamics of breast carcinomas in 
response to a variety of therapeutic measures.  Evaluation of treatment-induced changes 
in these two parameters contributes to the understanding of the tumor’s response (or 
resistance) to the therapy (172).  Chemotherapy, radiation therapy as well as 
immunotherapy heavily rely on apoptosis to kill breast cancer cells (244) and the changes 
that decrease the ability of cells to activate the apoptotic response may play a key role in 
resistance to these therapies.     
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Studies suggest that once arisen, cancers have a very low threshold for apoptosis, which 
may be a consequence to enhanced proliferation.  In contrast, a low threshold for 
apoptosis may not be a consequence of high rate of proliferation in normal cells e.g. 
intestinal epithelium.  This very fact is exploited by the cancer therapies that target the 
rapidly dividing – more sensitive cancer cell DNA by genotoxic agents.  Unfortunately 
cancer cells develop resistance for such therapies resulting in a deadly outcome.  
 Many death and survival genes, which are regulated by extracellular factors, are 
involved in apoptosis.  There appears to be a critical set of apoptotic mediators regardless 
of the initiating agent, which are regulated by various survival mechanisms.  These 
mechanisms are interconnected so that defects or manipulations in one can cause changes 
in the other (discussed in detail in the first part of this chapter).  Studies suggest that 
anticancer drugs kill susceptible breast cancer cells by inducing the expression of death 
receptor ligands such as Fas (FasL), which then bind and activate Fas and death receptor 
pathway via caspase 8 (250).  Interestingly most breast tumors express FasL as well as 
members of TNFα receptor family (29,139).  There seem to be controversies in data 
regarding such receptor and ligand functions, mostly due to discrepancies in tissue 
culture conditions and drug concentrations.  Additional studies are needed in breast 
cancer cell lines to determine the precise role of this membrane linked, extrinsic 
apoptosis pathway.  However, the intrinsic (mitochondrial pathway) has been shown to 
play an important role in most anticancer drug therapies.           
 Much of the work on apoptosis and breast cancer has focused on BCL2 and its 
family members.  BCL2 is important in pathogenesis of B-cell malignancies in human as 
the name implies (B-cell Lymphoma/Leukemia 2) but also plays a major role in other 
types of cancers.  It has been recognized as a proto-oncogene, activation of which leads 
to malignancies.  BCL2 family proteins play crucial roles in mitochondria-regulated cell 
death pathway (Figure 1.1.3.1).  Expression of anti-apoptotic BCL2 is increased by E2 in 
estrogen responsive MCF-7 (42) and breast cancer tissues (186).  Environmental 
estrogens are thought to mimic this effect as these agents suppress TNFα induced 
apoptosis in ER positive but not in ER negative cells (149).  Chemotherapeutic agents 
exert their effect also through BCL2 family members.  For an instance, paclitaxtel, 
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doxorubicin and thiotepa upregulate pro-apoptotic and down regulate anti-apoptotic 
members of the BCL2 family (37,186,206).  Some of these have been shown to sensitize 
MCF-7 cells to apoptosis by phosphorylating and inactivating BCL2 (256) related to 
activation of Cdc2, JNK and other kinases.  Introduction of anti-BCL2 antibody gene via 
a plasmid, enhanced the chemotherapy induced apoptosis in MCF-7 cells and may 
represent a novel approach to cancer therapy (213).   Microinjection of synthetic BCL2 
peptide was shown to reduce the apoptosis induced in renal tubular epithelial calls where 
as the BAK and BAX peptides induced apoptosis in otherwise untreated cells (209).  
Clinically, increased levels of BAX are correlated with a good response to chemo and 
radiotherapy, whereas increased levels of BCL2 and BCLxl are correlated with poor 
response (44,171,299).   
 Protein kinase B (Akt) is particularly important in breast cancer as a signal 
intermediate for survival factors such as IGF-1.  Dysregulation of Akt signaling as well 
as amplification of the Akt gene is a common occurrence in tumors (16,158,257).  Akt 
phosphorylates and regulates proteins involved in various cellular pathways including 
apoptosis.  Pro-apoptotic BAD and NFκB are examples for such Akt targets.  NFκB is 
activated, while BAD is inactivated by Akt (231,295), and both these actions promote 
cell survival.  The Ras/ERK pathway (one of several Ras oncogene pathways implicated 
in cancer) and Akt act in cooperation to induce NFκB activity (231).  In MCF-7 cells, 
Akt suppressed TNFα induced apoptosis, which also correlated with increased NFκB 
activation (26,30).  Further, a recent study shows a new model for anti-estrogen 
resistance that requires ERα activation by PI-3K and Akt in the absence of estrogen (43).                 
The caspases have been studied in in vitro cancer models as potential cancer therapeutic 
targets owing to their central role in apoptosis (Figure 1.1.3.1).  MCF-7 cells, which lack 
caspase 3 due to deletion in the caspase 3 gene (131), showed increased sensitivity to 
chemotherapeutic agents upon caspase 3 reconstitution (293).  Though caspase 3 is 
redundant in some settings, it is obviously a key factor towards an efficient apoptotic 
program.  Therefore further studies may show whether promoting crosstalks between 
extrinsic and intrinsic apoptotic pathways (that eventually activate caspase 3 and other 
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executor caspases), and upregulation of these caspases are indeed useful strategies of 
cancer therapy.   
 
1.2 Hypothesis and Rationale 
Estrogens are growth inducers in normal and cancer breast tissue and, are capable of 
inhibiting apoptosis in vitro and in animal models.  They appear to oppose apoptosis 
induced by intracellular (default death signals) as well as extra cellular factors such as 
chemotherapeutic agents.  The goal of this study is to understand the underlying 
mechanisms and dissect specific signal transduction pathways by which E2 exerts anti-
apoptotic effects in breast cancer cells.  Since growth of a malignant tumor is the sum of 
cell proliferation and cell death, understanding the factors that regulate both processes is 
crucial in understanding the biology of this cancer.  It is likely that E2 effects on MCF-7 
(and other ER positive breast cancer cells) are more pronounced than in normal breast 
epithelial cells. This may be a result of distinct biological changes that occur in cancer 
cells during oncogenic transformation.    
In response to intracellular and extracellular distress signals, cells enter a 
programmed death process called apoptosis.  This is executed by death proteases 
(caspases) that are tightly regulated in a normal healthy cell.  Among the mechanisms 
regulating caspase activity, BCL2 family of cytoplasmic proteins takes a centre stage.  
Pro- and anti-apoptotic members of this family interact with each other and integrate a 
diverse array of upstream survival and death signals and determine the fate of the cell.  
Disrupted regulation of apoptosis may be manifested as a variety of disorders.   
In the presence of survival factors, BCL2 family member BAD gets phosphorylated on 
two serine residues (75 and 99), which are consensus targets for Akt and ERK induced 
p90RSK.  Phosphorylated BAD is sequestrated in the cytosol by 14-3-3 molecules.  Non-
phosphorylated BAD binds with anti-apoptotic members of the family such as BCLxl and 
BCL2 and abolishes their activity towards cell survival.  
PI-3 kinase and its down stream targets mediate survival signals activated by a variety of 
agents in MCF-7 and other cell types (221).  In addition to its well known down stream 
effector Akt, PI-3K also has been shown to have effects on all MAPK pathways (286).  
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Activation of Akt and MAPK (specifically ERK) are known to support cell survival and 
growth, and their effects in MCF-7 breast cancer cell line are very well documented.         
 In this study we hypothesize that E2 induces inhibitory phosphorylation of pro-
apoptotic protein BAD at two serine residues through the activation of ERK and PI-3 
Kinase pathways, ensuring the survival of ER positive MCF-7 cells, in the presence of a 
host of apoptotic inducers.   
 
1.3 Results and Discussion  
Figure 1.3.1  
E2 effects on H2O2, TNFα and serum withdrawal induced apoptosis are mediated by 
PI-3 kinase 
Previous work in our laboratory has shown that estrogens decreased cell death and 
apoptosis induced in MCF-7 cells by mitogen withdrawal (7).  Recent work indicates that 
induction of cell growth by E2 in MCF-7 cells may require activity of the PI-3K pathway 
(176) and the Ras/ERK pathway (48).  Given this background we sought to determine if 
PI-3K plays an important role in E2 action with respect to cell growth and apoptosis.  In 
preliminary experiments we verified that E2 promoted cell survival/growth under low 
serum conditions and further established that the PI-3K inhibitor wortmannin inhibited 
this effect of E2.   
 
(A) To confirm the requirement of PI-3K activity for the cell survival induced by E2, 
MCF-7 cells were treated with E2 in the presence or absence of LY294002, a specific PI-
3K inhibitor (234) in serum free medium.  In the absence of E2, there was significant cell 
loss reflected in MTT uptake over a five-day period (n= 4, p<0.05).  E2 completely 
blocked this decrease and maintained MTT uptake at or above day 1 level.  Treatment 
with LY294002 abolished the ability of E2 to increase cell numbers as indicated by MTT 
uptake (day 2) or maintain cell survival (day 4, 5) and also reduced viability in the 
control cultures at day 4 and 5.  These results suggest that survival of MCF-7 cells under 
conditions of serum withdrawal requires PI-3K activity and that the ability of E2 to 
protect cells from death as well as to induce growth is blocked by abrogation of PI-3K 
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Figure 1.3.1
E2 effects on H2O2, TNFα and serum withdrawal induced apoptosis are
mediated by PI-3 kinase
(A) MCF-7 cells were treated as indicated and MTT assay was performed 
to measure amount of live cells
(B) Apoptosis was induced as indicated and DNA fragmentation was
assayed
(C-D) Western blot demonstrate the PARP cleavage and cytochrome-C
release in response to indicated agents. 
(E-G) MCF-7 cells expressing indicated constructs were treated with
various apoptotic agents and DNA fragmentation was assayed.
(H) Western blot demonstrates the exogenous expression of indicated
molecules 
(please see the text for detailed experimental conditions) 
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activity.   MTT results simply demonstrate the amount of live cells present under given 
conditions and, in the case of E2, this may reflect the sum of anti-apoptotic and mitogenic 
effects.    
 
(B) The above results and prior observations suggest that E2 may decrease apoptosis in 
MCF-7 cells.  Since TNFα induces apoptosis through activation of caspase8 and, or JNK 
activation (39) in a variety of cell types including MCF-7 cells (41,108,267).  We treated 
MCF-7 cells with TNFα in the presence of E2, 17-α estradiol (an estrogen of low 
potency), E2 plus an excess of the specific E2 antagonist, ICI 182,780.  TNFα increased 
apoptosis as measured by DNA fragmentation by 4-5 fold and E2 was able to reduce this 
effect significantly, whereas 17α-estradiol had no protective effect.  The presence of an 
excess of the E2 antagonist blocked the protective effect of E2 in TNFα treated cells.   
 
(C) Poly (ADP-ribose) polymerase (PARP) cleavage, a well-known late event in the 
apoptosis process (86) was induced by TNFα and this cleavage was significantly blocked 
by E2 pretreatment. 
The reactive oxygen species, H2O2, is known to induce apoptosis in a variety of 
cell types including MCF-7 cells (146) and this apoptotic effect is decreased by 
pretreatment with E2 or overexpression of BCL2 in a synergistic fashion (210).  
Furthermore, E2 and overexpression of BCL2 exhibit additive inhibitory effects on 
cleavage of PARP (86) induced by H2O2.  In confirmation of this data, we found that E2 
pretreatment can block DNA fragmentation as well as PARP cleavage induced by 2 mM 
H2O2 (Figure 1.3.1 B and C).  Pretreatment with 17-α estradiol had no significant 
protective effect against H2O2 suggesting that E2 effects are unlikely to be due to its 
potential free radical scavenger function (27).   
 
(D) Apoptotic effects of certain stimuli including those activating the extrinsic pathway 
are manifested at least in part via their effects on mitochondrial membrane integrity (82) 
(106). Release of cytochrome-C from dysfunctional mitochondria contributes to the 
formation of the apoptosome, which ultimately activates the downstream caspase 
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pathways (39).  Since the results presented in A-C would predict that E2 may preserve 
mitochondrial integrity in the presence of apoptotic stimuli, we sought to determine 
whether E2 would preserve mitochondrial integrity by assessing cytoplasmic cytochrome-
C protein level.  In untreated or E2 only treated cells, cytoplasmic cytochrome-C was 
undetectable.  As expected H2O2, TNFα and serum withdrawal increased cytochrome-C 
in the cytoplasm.  Co-treatment with E2 decreased cytochrome-C release induced by 
TNFα to a similar extent as that observed in cells co-treated with serum and TNFα.  
Taken together these results suggest that E2 protects cells against apoptosis induced by 
TNFα, H2O2 and serum withdrawal (not shown) possibly by maintaining mitochondrial 
integrity.     
 
(E, F, G) To establish the role of the PI-3K pathway in E2-induced anti-apoptosis, we 
used adenoviral vectors to interfere with operation of this pathway.  Cells were 
transduced with adenoviral wild type PTEN/MMAC that effectively decreases activity of 
the PI-3K pathway by dephosphorylation of PI-3K products (183,199).  Over-expression 
of PTEN completely blocked the ability of E2 or IGF-1 to prevent apoptosis induced by 
serum withdrawal (E), H2O2 (F) and TNFα (G) when compared to adenoviral LacZ 
(control) infected cultures.  Akt/PKB is a downstream target of PI-3K pathway that 
promotes cell survival in a number of cell types (69,81).  Similarly the overexpression of 
dominant negative Akt (DNAkt) enhanced apoptosis induced by the agents, and 
completely reversed the effects of either IGF-1 or E2 on apoptosis prevention.  These data 
together with data derived using chemical inhibitors strongly suggests that the PI-3K/Akt 
pathway is essential for the anti-apoptotic effects of E2 or IGF-1 in MCF-7 cells.  We 
repeatedly observed that DNA fragmentation (measured by the Cell Death ELISA) in 
viral transduced cells was below the levels observed in parental cells (1.8-2.5 vs. 4-5 fold, 
compare Figure 1.3.1B and E-G), which lead to an apparent decrease in the magnitude of 
apoptosis as measured by the cell death ELISA in the latter. 
 
(H) A Western blot analysis showing the expression of the indicated constructs in MCF-7 
cells.   
48
1.3.2 E2 induced rapid signal pathways impose phosphorylation on BAD  
Figure 1.3.2.1 
E2 activates the PI-3K/Akt pathway leading to phosphorylation of down stream 
targets 
The above data strongly suggests that the ability of E2 to decrease apoptosis in MCF-7 
cells is at least partly mediated by the PI-3K/Akt pathway.  Transient activation 
(measured by S473 phosphorylation) of Akt by E2 in MCF-7 cells has been reported 
(48,227).  Our data suggest that the PI-3K/Akt pathway may need to be activated for a 
prolonged period to maintain BAD in an inactivated (phosphorylated) state.   
 
(A) Kinetic behavior of the PI-3K response to E2 was measured.  PI-3K activation was 
determined by phosphorylation of IRS-1 on S612 by in vitro kinase assay using 
immunoprecipitates of the p85 subunit of PI-3K.  E2 was able to rapidly activate PI-3K 
approximately 3 fold, in growth arrested cells.  Similar in magnitude to the activation 
elicited by IGF-1.   
 
(B) A detailed time course of Akt catalytic activity in growth arrested MCF-7 cells, was 
measured by in vitro kinase assays (n=3) using Akt immunoprecipitates and BAD as the 
substrate.   
 
(C) GSK3β is a downstream target of Akt (65).  Active GSK3β effectively triggers rapid 
cyclin D1 turnover and affects the cell cycle regulation (77).  GSK3β activity was 
determined by in vitro kinase assay using immunoprecipitates of GSK3β.  E2 rapidly and 
strongly inhibited GSK3β activity.  As expected, another Akt activator IGF-1 also 
completely inhibited GSK3β activity.  The effect of E2 was sustained for 60 min (our 
unpublished data) and such a time course is compatible with the increase in cyclin D1 
protein observed 3-4 hrs after E2 addition to quiescent cells (94,95). 
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Figure 1.3.2.1
E2 activates the PI-3K/Akt pathway leading to phosphorylation of 
down stream targets
(A) In vitro kinase assay with PI-3kinase immunoprecipitataes and IRS-1
as the substrate.  Graph represents densitometry values from three 
independent experiments
(B) Time course for Akt activation by E2 growth arrested cells. Graph was
obtained from values of three independent experiments 
(C) In vitro kinase with GSK3β immunoprecipitataes and MBP as the
substrate
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Figure 1.3.2.2 
E2 activates ERKs and down stream target p90RSK 
A number of studies reported that E2 rapidly activates ERK1 and 2 in MCF-7 cells (130) 
and refs there in) and in a number of other cell types (152,246).  However, others failed 
to observe E2-mediated ERK activation in MCF-7 cells (47,85,176).   E2 induced ERK 
activity could be a result of activation of the Ras/Raf signal transduction pathway or may 
follow rapid increase in intracellular Ca2+ (130).  Previously we had demonstrated that 
increased cyclin D1 synthesis in response to estrogens is partly blocked by the MEK1 
inhibitor PD98059 and that dominant negative ERK2 partially inhibited the induction of 
cell cycle transit by estrogens (7).   
 
(A) Therefore we measured a detailed time course of ERK activation by E2.    
E2 rapidly activated ERK with maximum activation of five fold observed within 15 mins 
and significant ERK activation was sustained for at least 120 mins (n=4).   
 
(B) Enhancement of ERK activity by E2 was partly blocked by the specific estrogen 
antagonist ICI182, 780 and the PI-3K inhibitor LY294002. 
 
(C -D) It is known that p90RSK1 is phosphorylated at S364 and T574 residues by ERKs 
leading to its activation (67) and our results on BAD phosphorylation (C) imply that E2 
activates p90RSK1. Therefore we directly determined that E2 rapidly activates p90RSK1 by 
in vitro kinase assay using immunoprecipitates of p90RSK1 (D) which shows that p90RSK1 
is activated within 5min by E2.   
 
Figure 1.3.2.3 
Interactions of E2 induced signal pathways 
(A panels 1-3) Above results and other recent work (112,286) indicate that there is a 
crosstalk between the PI-3K and ERK pathways.  We explored this interaction further by 
over-expression of adeno viral PTEN.  E2 or IGF-1 activated ERKs in control Ad virus 
infected cells, PTEN over-expression (approximately 3X over the basal level [panel 3]) 
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Figure 1.3.2.2
E2 activates ERKs and down stream target p90RSK
(A) Time course of E2 activated ERK measured by in vitro kinase assays (n=4)
(B) Western blot demonstrating phosphorylation of ERKs in response to indicated 
agents.  (C) In vitro kinase assay (Non radioactive) using immunoprecipitates of p90RSK
and BAD as the substrate.  Western blot of the reaction demonstrates phospho 
BAD.  (D) In vitro kinase assay using with immunoprecipitates of p90RSK and MBP
as the substrate. Expression of p90RSK is shown in a Western blot  
C D
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Figure 1.3.2.3
Interactions of E2 induced signal pathways
(A) MCF-7 cells expressing indicated viral vectors were treated with IGF or
E2.  Western blot demonstrates the activation of ERK by phoshorylation (panel 1)
In vitro kinase assay with immunoprecipitates of ERK and MBP as the substrate
(panel 2).  Level of expression of  PTEN is shown in panel 3
(B) Panels 1-2 in vitro kinase assay with immunoprecipitates or Akt and p90RSK
Using BAD as the substrate.  
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partly blocked ERK activation observed at 15mins of treatment with these two agonists.  
In confirmation of the data using phosphospecific ERK antibodies, PTEN also partly 
inhibited ERK2 activity measured by MBP phosphorylation in an in vitro kinase assay  
(n=3) (panel 2).   
 
(B panels 1-2) In extracts from similarly treated cells, BAD phosphorylation by Akt and 
p90RSK1 were measured in vitro.  PTEN over-expression abolished the Akt and p90RSK1 
activation.   These results suggest that the PI-3K pathway may regulate the ERK response 
in addition to the Akt response in MCF-7 cells and provide evidence for cross talk 
between these signal pathways in response to E2 or IGF-1, under our experimental 
conditions.   
 
Figure 1.3.2.4 
E2 induces BAD phosphorylation 
(A panels 1-2) BAD is a pro-apoptotic BH3 domain-containing protein (5,106), which 
forms heterodimers with BCL2 or BCLxl (59) resulting in cytochrome-C release from 
mitochondria.  Anti-apoptotic agents like IGF-1 induce BAD phosphorylation at specific 
serine residues, and phosphorylated BAD is sequestered away from its site of action in 
the mitochondria by binding to cytosolic 14-3-3 proteins (70).  Since BAD is 
phosphorylated on serine 99 (S99) by Akt (70) and S75 is a target site for p90RSK1 (82), 
we ascertained the ability of E2 to induce phosphorylation of BAD at specific residues by 
using BAD phosphorylation site mutants as in vitro substrates [note: human S75 and S99 
are equivalent to S112 and S136 in mouse].  Clearly E2 or IGF-1 treated cell extracts 
were unable to induce phosphorylation of  the serine to alanine mutant (S75A) while S99 
phosphorylation was enhanced 3-4 fold.  Similar specificity was observed when the S99A 
BAD mutant was used as the substrate (panel 1).  When the double phosphorylation site 
mutant (DM) was used as a substrate, only a small fraction of the phosphorylation that 
was observed with single mutants was detectable.  Multiple immunoreactive bands have 
been previously observed when recombinant BAD was used as a substrate (70).        
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Figure 1.3.2.4
E2 induces BAD phosphorylation
(A) Panel 1-2, GST-tagged BAD mutants were used as in vitro substrates with 
E2 or IGF-1 induced cell lysates.  Reactions were Western blotted for 
phospho- and total BAD
(B-C) Western blot demonstrating endogenous BAD phosphorylation induced 
by indicated agents. 
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(B panels 1-2) In vivo BAD phosphorylation was also measured by Western blot 
analysis.  Following treatment with E2 or IGF-1 for 15mins both S75 and S99 
phosphorylations were enhanced (>3 fold) and total BAD levels were unchanged in this 
time frame.  Panel 2 shows a graph obtained from three independent experiments.    
 
(C) Since our results demonstrated that E2 can induce BAD phosphorylation in vitro and 
in vivo and can prevent cell death in response to several stimuli, we studied the possible 
changes in phosphorylation status of BAD during apoptosis induction.  E2 increased 
endogenous BAD phosphorylation at S75 and S99 above the basal level several fold 
whereas TNFα and H2O2 decreased it below control level.  Co-treatment with E2 and 
H2O2 or TNFα restored the BAD phosphorylation to above control levels.  Taken 
together these data strongly suggest that E2 as well as IGF-1 exert anti-apoptotic actions 
partly through phosphorylation and inactivation of the pro-apoptotic BAD protein, and 
that phosphorylation of BAD is a consequence of activation of Akt and ERK/p90RSK1  
 
1.3.3 BAD is a key mediator of E2 induced anti-apoptosis in MCF-7 cells 
Since the effects of apoptotic agents on decreasing BAD phosphorylation (inactivation) 
were largely reversed by E2, BAD inactivation could be a potential non-genomic effect of 
E2, which results in cell survival.  To better understand the involvement of BAD in cell 
death and survival in MCF-7 cells, experimental techniques were used to knock down the 
endogenous BAD and over-express wtBAD as well as phosphorylation site mutants of 
BAD.    
 
Figure 1.3.3.1  
Inhibition of BAD is a critical event in E2 induced anti-apoptosis in MCF-7 cells 
(A) MCF-7 cells transduced with antisense oligonucleotides to prevent the translation of 
BAD mRNA.  The antisense sequences, BAD antisense 1 (BAD As 1) containing the 
complementary sequence to the translation initiation codon and BAD antisense 2 (BAD 
As 2) containing the complementary sequence to the translation termination codon were 
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Figure 1.3.3.1
Inhibition of BAD is a critical event in E2 induced anti-apoptosis in
MCF7 cells
(A) Endogenous BAD was knocked down with anti sense mRNA to BAD.
Western blot demonstrates the efficiency of the reduction of BAD
(B) Quantification of apoptosis by flow cytometry in anti sense mRNA
treated cells in response to TNFα.  Change in the apoptotic population due to
TNFα is graphed against each cell population 
(C) DNA fragmentation assay to measure apoptosis in response to TNFα in
indicated cell populations 
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equally effective in downregulating BAD protein level whereas a scrambled 
oligonucleotide corresponding to BAD As1 (control oligo) was not.   
 
(B) Quantification of DNA by flow-cytometry revealed a large reduction of the sub G1 
fraction - apoptotic cells (203) in TNFα treated as well as serum-starved (not shown) 
cells in BAD As1 and BAD As2 treated, but not in control oligonucleotide treated cells.  
E2 did not have an additional effect alone or together with TNFα in anti-sense treated 
cells compared to control oligonucleotide treated cells (not shown).  Change in apoptosis 
due to TNFα was calculated by subtracting sub G1 fraction of untreated from sub G1 
fraction of TNFα treated cells for each oligonucleotide treated population.  Graph shows 
data from three independent experiments.  Introduction of BAD As1 or BAD As2 
significantly reduced the magnitude of apoptosis in response to TNFα (* = p<0.05), H2O2 
and complete serum starvation (not shown).   
 
(C) We next measured DNA fragmentation in oligonucleotide treated cells in the 
presence or absence of TNFα.  TNFα induced 4-5 fold DNA fragmentation above the 
basal level (comparable to Figure 1.3.1) in control oligonucleotide or Lipofectamine 
treated cells.  BAD As1 drastically reduced this effect (** = p<0.005) and maintained the 
DNA fragmentation near the basal level.  Similar results were observed using BAD As2 
(not shown).   This data clearly suggest a critical involvement of BAD in cell survival 
and death in response to several agents in MCF-7 breast cancer epithelial cells and agrees 
with the reduction in basal BAD phosphorylation induced by TNFα and H2O2 in the 
absence of E2 (Figure 1.3.2.4).  
 
Figure 1.3.3.2  
Functional serine phosphorylation sites are important for apoptotic function of BAD  
(A) To assess the effects on BAD in E2 induced cell survival and consequent changes in 
cellular morphology we transiently expressed wild type BAD (wtBAD) and dual 
phosphorylation site mutant of BAD (dmBAD) where S75 and S99 are mutated to 
unphosphorylatable alanine, together with an EGFP expression vector.  Following the 
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Figure 1.3.3.2
Functional serine phosphorylation sites are important for apoptotic 
function of BAD
(A) Cover slips cultures  of MCF-7 cells transfected with wild type or double 
phosphorylation site mutant together with EGFP, were treated as indicated.  
Nuclei were stained with Hoechst 33342.  Number of apoptotic nuclei in response to 
treatment is graphed for each cell group.
(B) Similarly treated cells were analyzed with confocal microscope to visualize 
cellular changes.
(C) Panel 1-3 Dose response for individual BAD vector in MCF-7 cells.  
In response to indicated agents, amount of apoptosis was assayed using DNA
fragmentation, in cells expressing varying amounts of vectors.  Panel 4, apoptotic 
response in pcDNAtransfected cells. 
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pcDNA
Figure 1.3.3.2 continued
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desired treatments, cover-slip cultures were stained with Hoechst 33342 and mounted on 
to glass slides.  E2 reduced the TNFα induced apoptosis in wtBAD expressing cells by 
>50% and importantly had no protective effect in dmBAD expressing cells.  Pre- 
treatment of E2 had the same protective effect against TNFα in cells expressing the 
control vector pcDNA3 or EGFP alone (not shown).  It must be emphasized that the 
overexpression of dmBAD did not alter the number of apoptotic nuclei compared to those 
in pcDNA3 or EGFP transfected cultures.  There is an absolute requirement for TNFα to 
induce apoptosis in dmBAD as well as wtBAD expressing cells.  The magnitude of 
apoptosis observed with cell counting (~ 8-9 fold) is somewhat higher than that observed 
with DNA fragmentation ELISA assay (4-5 fold in Figure 1.3.1) in response to TNFα.  
Possible explanation for such differences in magnitude may be the fact that only a 
fraction of all the cells (i.e. the transfected population) is counted in (A) whereas in 
Figure 1.3.1A, DNA fragmentation of the whole population is measured.             
 
(B) Similarly transfected and treated cells were examined by confocal microscopy to 
further analyze the cellular morphological changes. TNFα induced cellular shrinkage and 
atypical structure of nuclei in MCF-7 cells as has been previously described for fibroblast 
(182) and neuronal cells (45).  It was difficult to observe the chromatin clumping (typical 
for apoptosis) in TNFα treated cells due to shrinkage of the nuclei as opposed to this 
feature being readily apparent in paclitaxel treated cells (not shown).  Under these 
conditions expression of exogenous wtBAD or most importantly, dmBAD (white arrows 
in fluorescence images and respective differential interference contrast (DIC) images) did 
not enhance basal apoptosis (panel 1 and 4).  Treatment with TNFα in wt and dmBAD 
transfected cells clearly induced apoptotic changes (panel 2 and 5).  While E2 was able to 
impede morphological effects of TNFα in wtBAD expressing cells (panel 3) it was 
unable to counteract the effects of TNFα in dmBAD expressing cells (panel 6 and 7).  
Black arrows in panel 6 and 7 point to the untransfected cells that preserve the normal 
morphology.  Under these conditions expression of EGFP alone did not induce 
morphological changes (white arrows in the insert).  These observations further supports 
the proposed crucial role of BAD in MCF-7 cells and the critical importance of the two 
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specific phosphorylation sites in BAD for the anti-apoptotic effects of E2.  It is quite clear 
that dmBAD by itself does not induce apoptosis in the absence of TNFα.  This  suggests 
that in these mammary carcinoma cells, there are mechanisms to possibly sequester BAD 
away from mitochondria independent of S75 and S99 phosphorylation and binding to 14-
3-3 proteins, thus making dmBAD ineffective as an apoptosis inducer by itself.   
 
(C Panels 1-4) Anti-apoptotic effect of E2 was further evaluated in cells expressing 
increasing levels of BAD.   MCF-7 cells were transfected with 1/4x, 1/2x, 1x and 2x (x = 
regular dose = 0.6ug DNA for 10cm2) of each construct and were treated with TNFα with 
or without E2.  DNA fragmentation was assayed as described above.  E2 reduced 
apoptosis by 45-60 percent in the wtBAD expressing cells irrespective of the dose.  E2 
mediated protection was dampened by the overexpression of dmBAD by 50% or more 
(panel 1).  A moderate dose dependency in response to dmBAD was observed in TNFα 
as well as the E2+TNFα treated cells (panel 3).  The values of apoptosis as measured by 
ELISA in pcDNA3, wtBAD and dmBAD were unrelated to the dose of DNA.  Increasing 
doses of wtBAD did not influence the basal apoptosis, TNFα induced apoptosis or the 
protection offered by E2 (panel 2).  Panel 4 demonstrates the fold induction of apoptosis 
in pcDNA3 expressing cells at regular dose of DNA.  In wtBAD transfected cells (panels 
1 & 2) E2 is able to decrease the apoptosis due to TNFα to the same extent as in 
untransfected or pcDNA3 transfected cells (panel 4) by 50-60% when measured by this 
method.  Taken together this data strongly suggest that BAD is at least partly involved in 
E2 induced anti-apoptosis, and dmBAD is not an apoptosis inducer by itself in MCF-7 
cells.  This reinforces our notion that in these cells, TNFα (and perhaps other apoptotic 
stimuli) is able to translocate cytoplasmic BAD to its mitochondrial sites of action 
irrespective of phosphorylation at S75 and S99 residues.      
 
Figure 1.3.4  
E2 induced BAD phosphorylation requires Ras activated signaling pathways and 
Ras function is critical for cell survival of MCF-7 cells 
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Figure 1.3.4
E2 induced BAD phosphorylation requires Ras activated signaling
pathways, and Ras function is critical for cell survival of MCF7 cells
(A) Phosphorylation of endogenous BAD in response to indicated agents
demonstrated by Western blot.
(B) Endogenous and exogenous BAD phosphorylation in Ras
transfected cells in the presence and absence of E2.  Western blot 
demonstrates the expression of endogenous and exogenous Ras in MCF-7 cells  
(C) Quantification of apoptosis by counting apoptotic nuclei in indicated
cell populations.
63
(A) Previous studies in our laboratory had demonstrated that E2 induced p27kip1 
degradation and entry of quiescent MCF-7 cells into the cell cycle requires Ras activity 
(6,7,94).  Other investigators have demonstrated that E2 rapidly activated Ras in MCF-7 
cells (144) and recent work in our laboratory (93) demonstrated that Ras activity is 
required for nuclear export and degradation of p27kip1 in response to E2.  The 
phosphorylation of BAD at S75 and S99 has been proposed to be mediated by 
ERK/p90RSK1 and PI-3K/Akt pathways, respectively, in addition to other mechanisms 
(82).  Given the role of Ras discussed above and the evidence that the PI-3K and ERK 
pathways are activated by E2 (as discussed above) we used chemical inhibitors 
LY294002 and PD98059 to inhibit these pathways respectively and determined the 
effects of these treatments on BAD phosphorylation.  E2 induced BAD phosphorylation 
on S75 as well as S99 was completely abrogated by LY294002 supporting the idea of 
cross talk between the MAPK/p90RSK1 and PI-3K/Akt pathways.  Similarly, PD98059 
effectively reduced the phosphorylation of BAD at S75 as determined by Western blots, 
however the MEK inhibitor had considerably less effect on BAD S99 phosphorylation 
(compare E2 vs. PD+E2 on BAD phosphorylation on S99). None of the treatments 
changed total BAD levels in this time frame.     
 
(B) Since Ras is a well-known upstream regulator of the PI-3K/Akt and 
MEK/ERK/p90RSK1 pathways, we analyzed the effects of inhibition of endogenous Ras 
by using dominant negative Ras, RasN17 (DNRas) or selectively activating the 
MEK/ERK pathway with RasV12T35S (110) in transient transfection experiments.  Flag 
tagged BAD was co-transfected with control empty vector, RasN17 or RasV12T35S into 
MCF-7 cells.  Twenty-four hours after transfection, cells were serum withdrawn for 
another 24 hrs and stimulated with E2 for 15mins.  BAD phosphorylation was assessed by 
Western blotting.  Clearly the ability of E2 to increase both S75 and S99 phosphorylation 
(panel 1, lane2) of exogenous as well as endogenous BAD was inhibited by RasN17 (lane 
4) which by itself did not regulate BAD phosphorylation (lane3).  The MEK/ERK 
selective activator, RasV12T35S, by itself significantly activated BAD S75 
phosphorylation and moderately activated exogenous BAD S99 phosphorylation (lane 5) 
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and E2 was able to enhance this effect (lane 6).  Taken together the results in (A) and (B) 
strongly indicate that the ability of E2 to stimulate BAD phosphorylation and thereby 
prevent apoptosis is mediated through Ras activated MEK/ERK and PI-3K/Akt 
pathways.  Expression of endogenous and exogenous Ras is shown in panel 2.      
 
(C) To directly analyze the apoptotic effects of RasN17 in these cells, we stained nuclei 
of Ras transfected cells and studied them by confocal microscopy.  Nuclei corresponding 
to EGFP expressing cells (co-transfected with Ras or control vector) were counted, and 
the graph shows the number of fragmented nuclei as a percentage of total number of 
cells.  Transient expression of RasN17 induced 7-8 fold apoptosis over 48hr period where 
as the expression of RasV12T35S or empty vector had minimum effects on apoptosis 
observed in cells co-expressing EGFP.  These results demonstrate that Ras function is 
required to protect MCF-7 cells from dying even in the presence of growth medium and 
that this effect may be mediated at least partly by phosphorylating and inactivating pro-
apoptotic BAD.  The observation that E2 induced BAD phosphorylation was abolished by 
inactivation of endogenous Ras (B) further highlights the involvement of Ras mediated 
pathways in E2 signaling and demonstrates that Ras plays a critical role in the anti-
apoptosis mediated by E2 in MCF-7 breast cancer cells.                            
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Chapter 2  
BH3 Domain only Protein BAD Regulates Cell Cycle Progression  
by Modulating Transcriptional Activities of AP-1 
 
2.1 Introduction 
2.1.1 Functional Multiplicity of BAD 
BAD is a point where survival signaling pathways interact with the death machinery.  
Survival mechanisms inhibit BAD by adding inhibitory phospho groups on to it in order 
to prevent its participation in the apoptotic program.  Recently a BAD knockout mouse 
study (222) showed that survival factors are less protective against apoptotic insults when 
the BAD gene is knocked out.  Moreover, when the un-phosphorylatable BAD was 
“knocked-in” it did not increase cell death, yet increased the animal’ s susceptibility for 
carcinogens, highlighting the impact of BAD phosphorylation on three serine residues 
(75, 99 and 118 (murine 112, 136 and 155 respectively).  Absence of BAD in these 
animals also increased the incidence of some tumors like lymphoma.  This study 
concluded that BAD is a sensitizing intermediate through which survival factors set the 
threshold for apoptosis.  In the first part of our study (Chapter 1) we studied in detail, the 
importance of BAD phosphorylation on two of these critical serine sites, serine 75 and 99 
in E2 action as an anti-apoptotic agent.  Over-expressed wild type (wt) BAD or dual 
phosphorylation site mutant (dm) of BAD did not increase the basal death level in MCF-7 
cells.  When challenged with apoptotic stimuli, cells expressing wtBAD but not the 
dmBAD were remarkably protected against apoptosis by E2.  Our study and the BAD 
knockout mouse study emphasize the significance of functional phosphorylation sites of 
BAD for its role as an apoptotic mediator.                     
  Interestingly BAD was revealed to participate in nutrient metabolism, more 
precisely glucose, in mice (68).  Here BAD plays an essential role as an assembly factor 
for the glucose-metabolizing-enzyme complex at the mitochondrion.  BAD deficient 
mice displayed an abnormal glucose metabolism result from the inability to form the 
enzyme complex.  The most exciting finding was that the mice carrying un-
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phosphorylatable form of BAD showed a defective glucose metabolism though the 
enzyme complex was assembled normally.  This finding again suggests that 
phosphorylation and/or events secondary to phosphorylation are important for the 
“metabolic function” of BAD.  Although BAD is believed to be inactive after the 
phosphorylation on these serine residues, this “apoptotically inactive” molecule appears 
to posses the capacity to perform other tasks.       
 Growth promoting effects of BAD has also been shown.  Chicken embryo 
fibroblasts overexpressing wtBAD but not the control vector, increased their proliferation 
in the presence of growth factors.  This growth promoting effect of BAD was determined 
to be dependent on S99 phosphorylation and subsequent 14-3-3 binding (188).   All 
above findings suggest that BAD requires fully operative phosphorylation sites for its 
‘normal function’.  It is important to note that the normal function of BAD extends 
beyond the apoptosis regulation contributing to the balanced state of cell physiology.     
In our preliminary studies a wide spread expression of exogenous BAD was found 
in MCF-7 cells.  Similarly unphosphorylated and phosphorylated forms of endogenous 
BAD were found in the nuclei of proliferating breast cancer cells.  These observations 
warranted investigation of currently unknown nuclear functions of BAD in breast cancer 
cells and the second part of this study focuses on transcriptional effects of BAD on the 
cell cycle regulator protein cyclin D1.     
 
2.1.2 Activating Protein (AP-1) Transcription Factor Family 
AP-1 is a fundamental or critical class of transcription regulators that sense 
environmental information and translates it into expression of specific genes.  This family 
consists of several basic region leucine zipper (bZIP) domain proteins that homo- or 
hetero- dimerize in order to bind with the DNA targets.  The basic region harbors the 
actual DNA contact region and the leucine zipper enables the formation of the dimer with 
the partner molecule (Figure 2.1.2.1).  The characteristic feature of AP-1 complexes in 
the cell is the heterogeneity in dimer formation.  This results from the multiple AP-1 
subunits being expressed at the same time.  Originally AP-1 was divided into 4 main 
groups and sub-groups within them (276) .     
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AP-1 proteins dimerize through hydrophobic 
interactions between the amphipathic helices
DNA binding domain (basic region) binds 
in major groove on either side of the helix
(A)
(B)
ATF
2
junfo
s
jun
Figure 2.1.2.1
TGACCA TGACNCA
(AP-1/TRE) (CRE)
7 base pair target genes
cyclin D, Fra
8 base pair target genes 
c-jun, ATF3, cyclin A, D
(A) AP-1 proteins homo-or hetero dimerize through leucine zipper domain 
in order to bind with the DNA targets.  The basic region harbors the DNA 
contact region.  
(B) Jun/fos heterodimers preferentially bind to 7 base pair AP-1/TRE where as 
Jun/ATF-2 binds to 8 base pair CRE
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 The first group, AP-1 is composed of jun, fos and fra gene products.  Jun proteins 
form homo or hetero dimers with other members of the family and bind with high affinity 
to 7 base pair TRE (TGA G TCA), which is a phorbol ester 12-O- tetradecanoyl-phorbal-
13-asetate (TPA) response element (280).  Second group, ATF/CREB family proteins is 
further divided into two sub families (Table 2.1.2.1) depending on their binding 
partnerships.  First sub class (ATF1) either homo- or hetero-dimerizes with CREB and 
bind with cyclic AMP response element (CRE) which is 1 base pair longer than TRE 
(276).  Members of the second subclass (ATF2) complex with themselves as well as 
members of the first group (AP-1).  In addition to the intra-group partnerships, AP-1 
family transcription factors tend to interact with other non bZIP proteins (56,258).  This 
variation in dimer formation could direct the AP-1 factors to promoter elements that 
posses very minor resemblance to their consensus sites.  This in turn provides AP-1 
factors a high level of flexibility in gene regulation potential (276).    
  
AP-1 as a Mediator of Cell Proliferation, Survival and Death   
A plethora of physiological and pathological stimuli induce and activate AP-1 proteins.  
Studies using cells and mice deficient in individual AP-1 proteins have immensely 
contributed to the understanding of their physiological functions.  These involve the 
control of cell proliferation, growth, neoplastic transformation and apoptosis.     
Among growth regulators AP-1 proteins are unusual because they are up regulated in 
response to growth as well as stresses that cause cell cycle arrest and/or apoptosis.  This 
variable behavior might depend on the composition of AP-1 transcription complex, post-
translational modification of individual member as well as other interacting factors.  The 
clearest data on AP-1 induced apoptosis come from studies on the nervous system.  
Continuous c-fos activation was shown to precede neuronal cell death in response to 
neurotoxic agents (248).  Inhibition of c-jun activity by dominant negative form of c-jun 
protected neuronal cells from apoptosis induced by neuronal growth factor (NGF) 
withdrawal (205).  The activation of c-jun N-terminal Kinase (JNK) has been linked to 
induction of cell death in response to a variety of stimuli (25,52).  Expression of c-jun 
mutant (S63/73A) that cannot be phosphorylated by JNK was employed to effectively 
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Table 2.1.2.1
Classification of AP-1 Family Proteins and Their Preferred DNA Elements  
Family Sub Family Dimmers Target element/s
AP-1 Jun, Fos, Fra Homo and hetero 7 base pair TRE
ATF/CREB CREB and ATF1 Homo and hetero 8 base pair CRE 
(cyclic AMP 
response element)
ATF2-4, ATF6, 
ATFa
Homo and hetero 
dimers with 
themselves and 
Jun & Fos
8 base pair CRE
(cyclic AMP 
response element)
C/EBP Hetero dimers
with both above 
families
Data not available 
Maf Hetero dimers
with both above 
families
Data not available 
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block apoptosis (as effectively as JNK inhibitors) thereby showing the direct relationship 
between JNK and c-jun (92,238).  Interestingly, there are other reports on physiological 
and pathological conditions in nervous system where JNK activation precedes c-jun 
phosphorylation without inducing apoptosis (238).  Genotoxic stress induced apoptosis in 
response to UV radiation depends heavily on c-jun activation as demonstrated using c-jun 
and JNK null mouse fibroblast that are resistant to UV induced apoptosis (273).  
However in vivo observations show that AP-1 proteins in fact have protective roles in 
normal development.  C-jun deficient embryos show massive liver apoptosis, which 
might result in lethality (28).  Additionally JNK or c-jun independent apoptosis has been 
described in response to TNFα (174).   
 Different mechanisms of AP-1 actions described above may not be mutually 
exclusive.  Various stimuli could induce subsets of AP-1 regulated genes that support cell 
proliferation or survival, or in extreme conditions cell death.  AP-1 proteins, mostly 
members of Jun group, control cell growth through their ability to regulate the expression 
and function of cell cycle regulators such as cyclin D1, p53, p21(cip1/waf1), p19(ARF) 
and p16.  For instance, c-Jun is able to positively regulate cell proliferation through the 
repression of tumor suppressor gene expression and function, and induction of cyclin D1 
transcription (237,238,288).  JunB, which upregulates cell cycle inhibitory proteins and 
represses cyclin D1 (207), antagonizes these actions.  Table 2.1.2.2 summarizes the 
effects of Jun family proteins on cell cycle regulators.   
 
Cyclin D1 Regulation by AP-1 
Cyclin D1 protein regulates cell cycle progression at the G1 to S transition.  It interacts 
with the respective kinase partner, cyclin dependent kinase 4 (CDK4) to enhance its 
action.  This eventually results in the phosphorylation and inactivation of the 
retinoblastoma protein (Rb), which is inhibitory for the cell division (60).  The human 
cyclin D1 gene promoter sequence contains an AP-1 element at position -954 (9).  
Accordingly, several AP-1 proteins have been shown to bind to this site.  C-jun was 
shown to induce cyclin D1 transcription in transient expression studies (9) and 
phosphomimicking mutations of c-jun (mutation of serine 63 and serine 73 of c-jun to 
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Table 2.1.2.2
Effects of Jun Proteins on AP-1 Target Genes Involved in Cell Proliferation
Modified from Shaulian and Karin Oncogene 20: 2390-2400
Gene C-jun JunB JunD
Cyclin D
p16
p19
p53 and p21
Up
Down
-
Down
Down
Up
-
Down
-
-
Down
-
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negatively charged residues) further increased the extent of cyclin D transcription.  Fos 
group members cooperate with c-jun to induce cyclin D levels (36).  Whether cyclin D is 
the major mediator of AP-1 induced cell cycle progression was addressed by transducing 
cyclin D into c-jun -/- cells.  Only 30% of the DNA synthesis was restored by cyclin D 
introduction (288).  This demonstrates that AP-1 may require other effectors in addition 
to cyclin D to mediate its cell cycle effects (288).      
  
p53 Regulation by AP-1     
Another important c-jun target is p53, a negative regulator of cell proliferation.  C-jun 
negatively regulates p53 expression and its down stream functions.  In c-jun-/- cells a 
high basal p53 level was observed and this was reversed by stable expression of c-jun 
(235).  A direct relationship between these two players was established when an AP-1 
response element was found in the p53 promoter.  Interestingly, while c-jun is a potent 
activator when bound to its target sites, on p53 it appears to repress the transcription of 
the gene.  Most importantly deletion of p53 abrogated all cell cycle defects in c-jun -/- 
cells (235).  DNA damage by UV exposure often results in c-jun phosphorylation by JNK 
(discussed above).  On the other hand DNA damage triggers the up regulation of p53, 
which acts via p21 (cell cycle inhibitor) to suppress cell cycle progression.  It is well 
established that c-jun activation in this situation leads to the down regulation of p53 and 
relief the growth arrest.  Eventually cells may resume growth or may undergo apoptosis 
depending on the extent of DNA damage.  In some settings cells require c-jun to undergo 
apoptosis in response to UV damage (discussed above) and in another setting, cells 
increased sensitivity to UV induced apoptosis in the absence of c-jun (235).  These may 
appear contradictory yet may very well represent the true complexity of endogenous 
system that is governed by complex mechanisms mediated by multifaceted AP-1 
proteins.   
 Another AP-1 induced and apoptosis related molecule is FasL.  DNA damaging 
agents, which also activate JNK, such as UV, induce FasL.  AP-1 directly induced FasL 
transcription through the AP-1 binding element found in FasL promoter (138).   
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Regulation of c-jun by Phosphorylation 
C-jun is an immediate early gene whose expression level increases within an hour of the 
stimulation.  However, its transcriptional functions depend on post-translational 
modifications, namely phosphorylation.  About 8 phosphorylation sites of c-jun have 
been described to date.  Two N-terminal serine sites, 63 and 73 are largely accepted as 
the most critical residues pertaining to the transactivation function.  These are the well-
known targets of JNK (164) as well as ERK1 and 2 (196,197).  Upon phosphorylation of 
these residues conformational changes occur in c-jun to facilitate DNA binding (196 and 
refs therein).  Subsequently, several more residues were identified (threonine 231, 239, 
serine 243 and 249), that are proximal to the DNA binding domain.  Phosphorylation of 
these residues abolished c-jun and DNA binding (34).  In vivo and in vitro studies 
identified kinases such as GSK3, CK2, ERK1 and ERK2 as responsible (196 and refs 
therein).  This information suggested that c-jun activation requires phosphorylation of N-
terminal S63 and S73 and dephosphorylation of C-terminal residues.  Recently two more 
threonine residues (91 and 93) were identified whose phosphorylation was essential for 
the dephosphorylation of C-terminal residues.  It is the conformational change that results 
from T91 and 93 phosphorylation that facilitates the accesses of phosphatases to the C-
terminal sites (196).  Currently the exact kinase/s that are responsible for the 
phosphorylation of these residues are not known.  Evidence suggests that kinase other 
than JNK can be involved since in JNK null mice these sites were found to be 
phosphorylated (196).  Collectively, it is conceivable that full activation of c-jun may 
require N-terminal serine phosphorylation by JNK (also by ERK), and C-terminal 
dephosphorylation which depends on the phosphorylation of two N-terminal threonine 
residues whose in vivo upstream kinase/s are remained to be identified.                             
 
Estrogen Action on Cyclin D1 Promoter Depends on AP-1   
Estrogens are responsible for the proliferation of normal mammary epithelial and 
development and progression of breast cancer (Chapter 1.1 Introduction).  They act in 
early G1 phase of the cell cycle, and both steroidal and non-steroidal anti-estrogens arrest 
estrogen-dependent cell lines in the G1 phase (12,33,272).  Previous studies suggest that 
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cyclin D1 may be involved in mediating the estrogen induced cell proliferation in normal 
and malignant breast epithelial cells (24,94,264).  Cyclin D1 deficient mouse are 
defective in estrogen responsive proliferation of breast epithelium during pregnancy 
(242).  Estrogens induce MCF-7 cell cycle in conditions where mitogen activated protein 
kinases are continuously inhibited.  This correlated with the expression of cyclin D1 as 
well as the phosphorylation of retinoblastoma protein (12).  Interestingly the increased 
expression of cyclin D1 upon over-expression of estrogen receptor (ER) has been noted 
(38).  However, no ERE-related sequence has been found in the proximal cyclin D1 
promoter (115).      
 In addition to the classical ERE dependent mechanism, an alternative pathway of 
ER action has been described.  Here ER induces certain promoters that express AP-1 
protein binding sites (49,99,159).  The fundamental facts of ER action on AP-1/TRE 
elements have been demonstrated by several groups.  First, DNA binding of Jun and Fos 
is needed for ER action, and ER appears to increase the intrinsic transcriptional activity 
of these factors when bound to DNA (160,212,274).   Next, SERMs are able to active 
AP-1 target genes through binding to ERβ (187,284).  Genetic dissection of ERα has 
provided important clues on the mechanism of ER action on AP-1.  Activation functions 
(AF-1/AF-2) dependent and independent pathways of ERα have been shown to be 
important in estrogen induced AP-1 activities.  In the AF dependent pathway, estrogen-
ER actions points to the function of co-activator molecules.  ER was shown to interact 
specifically with Jun proteins, but not with the Fos family proteins (271).  Contrary to 
this, isolated ligand binding domain (LBD) of ER was shown unable to directly bind with 
AP-1 proteins, though it was able to induce AP-1 action (285).  Hence the most 
conceivable mechanism could be that, ER may bind with the Jun/Fos recruited co-
activator complex, which includes p300, CBP as well as p160 (100,271).  ER could join 
the already recruited activator complex at the AP-1 binding sites and trigger the co-
activator function to a higher state (160).  This triggering model may explain how 
estrogen-ER could have promoter specific effects i.e. the promoters that carry more 
elements in addition to ERE may be more responsive to estrogen.                  
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In the AF independent pathway, which has been observed in response to SERMs, ER 
appears to activate AP-1 mediated transcription without directly participating in the AP-1 
complex.  The finding that ER interacts with transcriptional co-repressors such as N-CoR 
only in the presence of SERM (284) suggests that ER may sequester N-coR and 
associated repressors namely histone deacytalases (HDACs) away from the AP-1 binding 
sites.  This may allow the histone acetylases (HAT) in the co-activator complex (recruited 
by Jun/Fos) to act without inhibition (98).  It is interesting to note that neither of these 
models requires ER and AP-1 protein direct interactions, or the DNA Binding domain 
(DBD) of ER.   
 The mechanism by which estrogen induces cyclin D1 in ERα positive cells has 
been linked to AP-1 responsive sites in the promoter.  Among the known cyclin D1 
promoter elements are AP-1/TRE and CRE (115) both of which can be activated by AP-1 
protein binding (Figure 2.1.2.1B).  The minimal cis-acting element in the cyclin D1 
promoter responsive to estrogen was mapped to position –96 to –26, which contains a 
putative CRE (232).  Mutations in this region caused complete loss of estrogen 
responsiveness suggesting an essential role of this element in mediating estrogen effect.  
Agreeing with the previous observations (276), c-jun and ATF-2 heterodimers were 
shown to be the most effective transcription factor in CRE transcription, and estrogen 
enhanced that basal effect.  Remarkably, isolated CRE sequence of the cyclin D1 
promoter was unable to induce transcription when removed from its natural environment 
(232).  This shows the importance of adjacent DNA for CRE function. They may play a 
role in recruitment of co-regulators to the CRE site.  This study also shows that the DNA 
binding domain and the activation function of ER are important for cyclin D1 induction 
by estrogen.   
 Estrogen induces c-jun expression as well as phosphorylation in an ER dependent 
manner (217,232), but does not affect expression of ATF-2 (232).   Therefore, it is likely 
that ER plays a dual role in cyclin D1 expression (i) through activating c-jun and (ii) 
acting as a co-activator for c-jun/ATF-2 dimer thereby increasing CRE transcriptional 
activity (Figure 2.1.2.2).   
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Figure 2.1.2.2
Possible estrogen/ER and AP-1 actions at the cyclin D1 promoter
Estrogen induces c-jun expression as well as its phosphorylation in an ER dependent
manner.  ER plays a dual role in cyclin D1 expression (1) through activating c-jun 
and  (2) acting as a co-activator for c-jun/ATF-2 dimer thereby increasing CRE 
transcriptional activity
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2.2 Hypothesis and Rationale 
Preliminary observations that over-expressed wild type BAD inhibits cell cycle transit in 
MCF-7 cells led us to investigate likely cell cycle regulatory effects of this molecule.   
Additionally, BAD abolished the activating protein response element (AP-1/TRE 
luciferase) activation in MCF-7 and T47D cells.  E2 induced cell cycle progression 
depends on cyclin D1 and associated kinases as has been previously shown.  Since cyclin 
D1 carries an active AP-1/TRE element at position –953 of its promoter, we hypothesized 
that BAD induced cell cycle block may result at least partly from an inhibitory action on 
this DNA element.   
Presence of endogenous as well as exogenous BAD in the nucleus raised our 
curiosity as how this translocation could occur since BAD does not contain a typical 
nuclear localization signal (NLS), and there is no information about another molecule 
that may bind to BAD and facilitate its nuclear import.  BAD co-immunoprecipitated 
with c-jun, which is a critical regulator of AP-1 functions, in the nuclear extract.  This 
observation led to the hypothesis that BAD binds with c-jun as a normal regulatory 
mechanism and when present in extra amount further sequesters c-jun away from its site 
of action.  Binding with c-jun and/or a subsequent step may facilitate BAD’s 
translocation to the nucleus.           
Further we hypothesize that the functional phosphorylation sites, S75 and S99 are 
important for this transcriptional regulatory function of BAD since the dual 
phosphorylation site mutant was incapable of inducing cell cycle block and the AP-1 
transactivation.   
 
2.3 Results and Discussion  
Figure 2.3.1  
Over expression of BH3 only BAD impedes the breast cancer cell growth in culture 
Two plasmid constructs (Flag-BAD and GFP-BAD) were used to over-express BAD in 
MCF-7 as well as T47D, breast cancer cells.  Presence of high amount of BAD did not 
kill these cells as we had observed previously (in contrast to the observations made by 
other authors).  However BAD appeared to slow down the rate of their proliferation as 
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Figure 2.3.1
Over expression of BAD impedes the breast cancer cell growth in culture
(A) MCF-7 cells were transfected with the indicated constructs, growth arrested and 
induced with E2.  DNA profile was assayed.  Percent of S/G2 fraction is shown in the 
graph. (B) Cells expressing the indicated BAD constructs and cells where 
endogenous BAD was knockdown (siRNA) were kept in complete growth medium 
for indicated times and S/G2 fraction was analyzed (n=2). (C -D) Cells transfected 
and treated as in (A) were lysed and whole cell lysate was used for Western blot 
analysis.  (E) asynchronous cells were transfected as indicated and Western blot 
analysis was done as in (C).   
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judged by visual observation of transfected cells.  This observation prompted us to 
investigate whether in addition to its pro-apoptotic functions BAD plays any role in cell 
cycle progression.   
 
(A) MCF-7 cells were growth arrested at G1/G0 using anti-estrogen ICI182, 780 in low 
serum conditions for 48 hours and induced with 5-10 nM E2 for 17 hours.  As measure of 
cell cycle progression, the DNA profile was analyzed by flow cytometry.  Change in 
S/G2 fraction is graphed for various treatment conditions (n=4).  BAD over-expression 
remarkably blocked E2 induced G1-S progression compared to control vector 
(pcDNA3.1) transfected or untrasfected cells (p<0.005).  Similar inhibitory effect was 
observed in BAD transfected cells in response to 5% FBS (not shown).  Since known 
BAD’s functions are mostly tied to its phosphorylation status, we questioned whether a 
relationship would exist between cell cycle regulatory function of BAD and its 
phosphorylation level.  Dual phosphorylation site mutant (dmBAD) was expressed, 
growth arrested and treated as described above.  Expression of dmBAD did not block the 
effect of E2 on cell cycle progression as cells entered S phase in the presence of E2 as 
much as observed in pcDNA3.1 transfected cells.         
 
(B) Cells expressing indicated constructs or cells in which endogenous BAD was 
inhibited by siRNA, were maintained in complete growth medium.  At indicated times 
cells were harvested and DNA profile was analyzed.  Mean values S/G2 fraction from 
two independent experiments with duplicates for each treatment are shown.  Marked 
reduction of S/G2 fraction by wild type BAD was observed at 48 hr post-transfection.  
Increased S/G2 fraction is apparent with BAD siRNA at 72 hr post-transfection, which 
clearly correlated with the expression levels of cyclin D1 (E).        
 
(C) E2 induced MCF-7 cell cycle progression through the regulation of cyclin D1 protein 
(12,95,263).  Since BAD abolished E2 induced cell cycle progression, a logical question 
is whether BAD influences the cyclin D1 level in these cells.  Cells were transfected and 
growth arrested as described in (A) and treated with E2 or 5% serum for indicated 
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periods.  Whole cell extracts were obtained and Western blot analyses were performed 
using the indicated antibodies.  E2 up-regulated cyclin D1 in control cells, but not in 
wtBAD over-expressing cells.  Further, wtBAD over-expression completely prevented 
serum from inducing cyclin D.  These results indicate that cell cycle regulation by BAD 
requires its phosphorylation at S75 and S99.     
 
(D) Various BAD mutant constructs were used to further elaborate involvement of BAD 
phosphorylation sites and other domains.  Single phosphorylation site mutants of BAD 
had variable effects, where as the dmBAD was completely incapable of inhibiting cyclin 
D response in E2 induced cells.  This data suggests the involvement of functional 
phosphorylation sites in BAD’s action.  Further strengthening this idea, a BH3 domain 
mutant of BAD, which cannot interact with other BCL2 family members, but carries 
intact S75 and S99 phosphorylation sites, had an inhibitory effect similar to the wild type 
protein.  
 
(E) Asynchronous MCF-7 cells were transfected with siRNA for endogenous BAD.  At 
indicated times, cells were harvested and total protein was used in Western blot analysis.  
siRNA treatment at 72 hrs inhibited endogenous BAD >75%.  Marked increase in cyclin 
D1 protein expression was observed that correlated with the reduction in BAD 
expression.  Data presented is a representative of two independent experiments with 
comparable results.       
 
In (C-D) exogenous BAD expression is assayed by Western blot analysis using anti-Flag 
antibody, and as a protein loading control, levels of actin are shown.  Western blots 
shown are representatives of at least three experiments performed, with comparable 
results.      
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Figure 2.3.2  
Cyclin D1 is a Transcriptional Target for BAD 
Reduced cyclin D1 protein levels in response to an excess amount of BAD could reflect 
the destabilization of the protein and/or negative regulation of its transcription and/or 
translation.  Therefore, effects of BAD on cyclin D1 transcription and translation were 
assayed.       
 
(A -B) Metabolic labeling of cultures with 35(S) labeled methionine was used to detect 
efficiency of cyclin D1 synthesis in asynchronous (A) as well as synchronous (G1 
arrested) MCF-7 cultures in response to E2 (B).  Cells were transfected and treated as 
indicated.  Cyclin D1 immunoprecipitates of each sample were resolved in SDS-PAGE.  
Gels were dried and autoradiograms were obtained.  Over-expression of wtBAD 
significantly reduced the basal cyclin D1 synthesis in asynchronous cells.  E2 enhanced 
the synthesis of cyclin D1 in growth-arrested cells in a time dependent manner.  BAD 
completely abolished this effect at 2 hrs and partially at 4 hrs, demonstrating the ability to 
negatively regulate cyclin D1 production in response to a specific mitogenic stimuli as 
well as in complete growth medium.  Neither BAD nor control vector expression 
influenced the newly synthesized CDK4 and CDK2 as observed with the 
immunoprecipitates of these proteins (B bottom panels).  Amount of actin in the input is 
shown as a protein control for the immunoprecipitions.  Autoradiograms shown are the 
representatives of at least three independent experiments with comparable results.    
 
(C) A cyclin D1 promoter construct was used to demonstrate the involvement of BAD in 
cyclin D1 transcription control.  Over-expression of BAD significantly reduced the 
promoter activity measured by the activity of the luciferase gene product (* p<0.0001); 
whereas expression of dmBAD had no negative effect on the cyclin D1 promoter.  BAD 
induced inactivation of the cyclin D1 promoter is comparable to that was observed with 
synchrony of cells at G1 phase.  Data presented is from three independent experiments 
with duplicates for each sample, with comparable results. 
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Figure 2.3.2
Cyclin D1 is a transcriptional target of BAD
(A) Proliferating cultures of MCF-7 cells transfected with the indicated constructs 
were labeled with 35(S) methionine for 2 hrs.  Total cyclin D1 was 
immnoprecipitated and newly synthesized cyclin D1 is shown in the radiogram.  
Bottom panel shows a Western blot of actin as the loading control. (B) MCF-7 
cells expressing indicated constructs were growth arrested and induced with E2
(10nM).  35(S) methionine was added simultaneously with E2.  Newly synthesized 
cyclin D1, CDK2 and CDK4 were detected by immunoprecipitation as described 
in (A).  (C) Cyclin D1 promoter luciferase was co-expressed in MCF-7 cells with 
indicated constructs (1/3 of the total DNA content).  Luciferase activity was 
assayed 36 hr post-transfection. (D) Cyclin D1 promoter mutants (CRE single and 
CRE/TRE double mutant) were used as in (C) (n=2). (E) TRE mutant of cyclin D1 
promoter was used with or without BAD as in (C) (n=2).    
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(D) Mutant constructs of cyclin D1, CRE single mutant (CRE mut) and CRE and AP-
1/TRE double mutant (CRE/TRE mut) preceding luciferase gene were expressed in 
MCF-7 cells with indicated BAD constructs or control plasmid.  Relative luciferase 
activity 36 hr post trasnfection is shown in the graph.  wtBAD failed to inactivate the 
cyclin D1 promoter when CRE is mutated, showing that BAD’s influence is essentially 
mediated through the CRE rather than AP-1/TRE in this natural promoter.  This 
observation agrees with the suggested critical role for CRE in cyclin D1 transcription in 
breast cancer cell. 
 
(E) A TRE mutant of cyclin D1 promoter (intact CRE) was used to further demonstrate 
the specificity of BAD’s effect.  wtBAD significantly inhibited the reporter activity 
showing supporting the data in (D).  Data from two independent experiments with 
duplicated samples are shown in the graph.                
 
Figure 2.3.3  
BAD targets AP-1/TRE Element through Association with AP-1 Proteins 
The evidence in Figure 2.3.1 argues that BAD can decrease synthesis of cyclin D1 as 
well as the activity of its promoter.  The promoter of cyclin D is highly complex and is 
composed of various regulatory elements such as AP-1/TRE, SP-1 and CRE.  Importance 
of AP-1/TRE and CRE for the cyclin D promoter activity in response to various agents 
has been shown previously (115).  Data in Figure 2.3.2D-E shows the importance of 
these elements in the context of BAD regulatory effects.  Influence of BAD on the 
activation of these elements was further determined.     
 
(A-B) MCF-7 cells were transfected with AP-1/TRE luciferase with wtBAD or empty 
vector pcDNA3.  In asynchronous (A) and synchronous (G1) (B) cells the basal and E2 
induced AP-1/TRE activation was measured.  Over expression of BAD significantly (*p< 
0.05) reduced the basal AP-1/TRE transactivation in asynchronous as well as 
synchronous cells.  E2 induced reporter activation (# p< 0.005) was significantly inhibited 
by the expression of BAD, but not the empty vector.  Comparable data was obtained 
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Figure 2.3.3
BAD targets AP-1/TRE element through association of the AP-1 proteins
(A-B) MCF-7 cells were transfected with AP-1/TRE (control vector tetracycline 
response element) luciferase with wtBAD or empty vector pcDNA3. In asynchronous 
(A) and synchronous (B) cells the AP-1/TRE activation was measured. (C) EMSA 
assay with indicated nuclear extracts. Panel on the right shows the efficiency of c-jun 
and BAD depletions from the nuclear extract.  
(D) EMSA assay with indicated nuclear extracts. Labeled NFκB sequence was used 
as a control probe. Bottom panel shows the expression of BAD in indicated nuclear 
extracts.  (E) Western blot shows c-jun in immunoprecipitates of BAD from indicated 
MCF-7 extracts and E2F levles were determined by WB. (F) Western blot shows c-
jun in immunoprecipitates of indicated proteins from MCF-7 nuclear extracts.  (G)
Immunoprecipitates of BAD or Flag from the indicated nuclear extracts were 
Western blotted for phosphorylated and unphosphorylated c-jun.  (H) Western blot 
demonstrating expression of the indicated proteins in the nuclear extract input for (G) 
Immnoprecipitates
from nuclear extracts
(F)
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using T47D breast cancer cells (data not shown).  As a control, tetracycline response 
element luciferase (TRE) was used.  BAD or pcDNA3 co-expression did not influence 
the activity of this reporter (A), which does not carry an AP-1 element.    
 
(C) To further assess the BAD influence on AP-1/TRE element, radio labeled element 
sequence (TGACTCA) was used as a probe in an electro mobility shift (EMSA) assay.  
Indicated nuclear extracts were incubated with the probe and change in nuclear factor 
binding was evaluated.  Depletion of BAD from the nuclear extract (lane 3) reduced the 
nuclear extract and labeled probe binding to the same extent as did by c-jun depletion 
(lane 5).  BCL2 depletion on the other hand, did not reduce the interaction between probe 
and nuclear factors.  Western blot shows the efficiency of depletion of the indicated 
molecules from the nuclear extract.   
 
(D) In the presence of exogenous BAD (lane 3) the nuclear factor and probe binding was 
significantly lower than that of control extract (lane 2).  This effect was reversed when 
endogenous BAD was inhibited by BAD anti-sense mRNA (lane 4).  Labeled sequence 
of NFκB was used as a control.  Over-expression or diminution of BAD did not influence 
nuclear factors and NFκB binding.  Western blot shows the expression of endogenous 
and exogenous BAD in the nuclear extracts.          
 Data from EMSA studies show that depletion of BAD from the nuclear extract or 
expression of exogenous BAD had inhibitory effects on AP-1/TRE element - nuclear 
factor binding.  This could suggest that BAD interacts with AP-1/TRE element DNA 
binding factors in the nuclear extract and that when BAD is depleted from the latter, 
those that are bound to BAD are also removed.  When in excess, BAD might compete 
with DNA binding by these factors and therefore decrease binding of nuclear factors to 
DNA.  This is conceivable since a reduction of probe binding instead a supershift (which 
would indicate BAD/nuclear factor binding to DNA), which is observed in response to 
BAD over-expression (lane 3)          
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(E-F) Given that c-jun is one of the nuclear proteins that bind to the AP-1/TRE element 
we sought to determine whether BAD interacts with c-jun.  Furthermore, c-jun has also 
been shown to participate in AP-1 dependent cyclin D transcription (9).  Endogenous 
BAD complexed with c-jun in the nucleus but not in the cytoplasm of proliferating MCF-
7 cells (E).  BCL2 did not complex with c-jun under this condition demonstrating the 
specificity of BAD and c-jun interaction (F).  E2F1 was measured as a nuclear marker.       
 
(G) Gene transactivation functions of c-jun are regulated by its phosphorylation status.  
We determined whether BAD and c-jun interaction depends on the phosphorylation of c-
jun by measuring active c-jun (N-terminal phosphorylation at S63 and S73) levels in 
BAD immunoprecipitates.  Unphosphorylated but not the phosphorylated form of c-jun 
was immunoprecipitated by endogenous as well as exogenous BAD in the nuclear 
extracts.   
 
(H) Nuclear extract used in (G) was assayed for the expression of various proteins by 
Western blot.  In BAD overexpressing cells, amount of c-jun phosphorylation is 
markedly low compared to control as well as BAD antisense treated cells.  Of note, 
expression of total c-jun was not changed either by increasing or reducing the level of 
BAD in these cells.   
 
Figure 2.3.4  
BAD Inhibits c-jun Phosphorylation via Signal Transduction Mechanisms 
(A) The data above suggests that BAD could prevent AP-1/TRE activation via its effects 
on c-jun.  In normal conditions BAD appears to physically interact with un-
phosphorylated c-jun in the nucleus (Figure 2.3.3.G).  Since the over-expression of BAD 
completely abolished c-jun phosphorylation, we questioned, in addition to physical 
interaction, which is evident under normal conditions with endogenous BAD, whether 
exogenous BAD could prevent c-jun being phosphorylated by upstream kinases, thereby 
inhibiting its DNA binding.  Activities of c-jun kinases were assayed by their 
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Figure 2.3.4
BAD inhibits c-jun phosphorylation via signal transduction mechanisms
(A) MCF-7 transfected with indicated constructs were growth arrested and
treated with E2 or serum for 3 hrs.  Western blot demonstrates the expression of 
indicated proteins in the whole cell extract.
(B) AP-1/TRE luciferase (1/4 of total DNA) was expressed in MCF-7 with 
indicated constructs.  BAD or empty vector pcDNA3 was introduced at 1:1 ratio 
with the signaling intermediates. 
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phosphorylation status.  In serum treated cells, active JNK induced c-jun 
phosphorylation, and this was inhibited by BAD over-expression (lanes 2 and 5).   
 E2 increased c-jun phosphorylation considerably through a mechanism, which 
appears to be JNK-independent.  This correlated with the phosphorylation of ERK1 and 
2, which was also inhibited by BAD overexpression (lanes 3 and 6).  This suggests that c-
jun activation in response to serum and E2 are mediated by different mechanisms.  BAD 
when overexpressed at least partly inhibit these mechanisms.    
Expression of dmBAD did not have any effect on the signal molecules despite its 
comparable expression to wtBAD (lanes 7-9) suggesting an important role for 
phosphorylation in the signal transducing effects of BAD.  The Western blot shown is a 
representative of more than three independent experiments with comparable results.  
 
(B) To further clarify the effects of BAD on extra cellular signal activated protein 
kinases, activated constructs of signal intermediates were used.  Expression of activated 
form of MEK1 and RasV12S35T mutant, both if which specifically activate ERK1 and 2 
increased the AP-1 luciferase activity 8-10 fold above basal level.  This effect is 
significantly reduced by the co-expression of BAD (at 1:1 ratio).  The activity elicited by 
MyrAKT (constitutively activated) was not interfered by BAD, indicating a specific 
effect of BAD on the Ras/ERK signal pathway.  Data from two independent experiments 
with two replicates per each treatment was used in the graph.  Since our data shows that 
BAD can inhibit MEK1 mediated AP-1 activation, BAD might regulate ERK activation 
or downstream events which result in c-jun phosphorylation.           
 
Figure 2.3.5  
Inhibitory Effects of Over-expressed BAD on AP-1/TRE Functions Depend on its 
Phosphorylation  
Cellular functions of BAD are mostly regulated by its level of phosphorylation i.e. hypo-
phosphorylated BAD is apoptotically more active than the hyper-phosphorylated form.  
We wondered whether the nuclear effects of BAD would also depend on its 
phosphorylation, if so, to what extent.  Phosphorylation site mutant BAD (dmBAD), 
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(B)
Endo.BAD -green
Nuclei – blue
Endo.phospho BAD 
S112– green
Nuclei – blue
Endo.phospho BAD
S136 – green 
Nuclei – blue
Figure 2.3.5
Inhibitory effects of over-expressed BAD on AP-1/TRE functions are 
dependent on its phosphorylation status
(A) Extracts of proliferating MCF-7 and T47D cells were analyzed by Western blots 
to detect phosphorylated and total BAD.  
(B) Fluorescent images of immuno histochemically stained MCF-7 cells.  
Endogenous BAD (phosorylated and unphoshorylated) is shown in green and nuclei 
in blue.  Images were merged to demonstrate BAD localization in the nucleus.  
(C) Nuclear extracts of MCF-7 cells expressing various BAD mutants were 
analyzed by Western blot.  Phosphorylation of BAD is detected using anti phospho 
BAD S75 and S99 antibodies.  
(D) Indicated BAD mutants were co-expressed with AP-1/TRE luciferase reporter 
(1/4 of total DNA) in MCF-7 cells.  Luciferase activity was assayed 36hr post 
transfection.  
(E) EMSA with indicated nuclear extracts and labeled AP-1/TRE element. 
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when expressed to the same level could not negatively regulate the cell cycle or the 
cyclin D1 protein level, as did the wtBAD (Figure 2.3.1A, C).   
 
(A) Expression pattern of phosphorylated form of BAD was assayed in various cell 
compartments.  In proliferating breast cancer cells (MCF-7 and T47D), endogenous BAD 
is present in nucleus and cytoplasm as shown by Western blots.  However the level of 
phosphorylated forms in the nucleus is very low compared to cytoplasm.  This suggests 
that the endogenous AP-1/TRE regulatory effects of BAD may not depend on its 
phosphorylation status.  Similarly only the unphosphorylated endogenous BAD could 
complex with c-jun in the nucleus (Figure 2.3.3 F and data not shown).  Data shown is a 
representative of three independent experiments with similar results.   
 
(B) Immuno histochemistry technique was used to detect endogenous BAD in MCF-7 
cells.  Cells were incubated with BAD antibodies (total, phos BAD S75 and phos BAD 
S99) followed by fluorescent conjugated secondary antibodies (green).  Nuclei were 
stained with Hoechst 33342 (blue).  Images were merged to demonstrate localization of 
BAD in the nucleus.  Images shown are the representatives of three or more experiments 
with comparable data.                
 Considering our observation that excess amount of wt BAD but not dmBAD plays 
a negative role on AP-1/TRE mediated cell cycle progression, it is reasonable to 
speculate that the inhibitory effect of BAD is phosphorylation dependent.  If so, over-
expressed BAD should be found in the nucleus.     
 
(C) Various BAD mutants were expressed and nuclear extracts were assayed.  Almost all 
the mutants expressed were present in the nucleus and they are phosphorylated on 
relevant residues in contrast to endogenous BAD.  Note: Flag-BAD vectors give rise to 
two immunoreactive bands in Western blots.  One at 23-25kD and the other around 30-
35kD.  The discrepancy between nuclear distributions of phosphorylated endogenous and 
exogenous BAD may relate to nuclear accumulation and dephosphorylation of these 
molecules in addition to other factors.        
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(D-E) Whether the dormant role of dmBAD in cell cycle regulation is a reflection of its 
effect on AP-1/TRE element was the next question we addressed.  AP-1/TRE luciferase 
reporter assay (D) as well as the EMSA (E) clearly shows the neutral effects of dmBAD 
on this element.  Graph in (D) was obtained from at least three independent experiments.  
Autoradiogram in (E) is a representative of two experiments with comparable results.         
 Collectively the data in this study show that (1) BAD has a regulatory role on AP-
1/TRE mediated expression of cyclin D1.  This effect is mediated by physical interaction 
with c-jun and possible sequestration from its site of action or from its activating kinases.  
It is very likely that, this effect of BAD at least partly contributes to the equilibrium state 
of AP-1/TRE functions, which are diverse and complex.  (2) When present in excess, 
BAD appears to intervene with the c-jun phosphorylation (Figure 2.3.4A), in addition to 
physical interaction (Figure 2.3.3G).  Both of these effects could contribute to the 
observed inhibitory effect.  Interestingly the effects of exogenous BAD appear to depend 
on the functional phosphorylation sites.   
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Chapter 3 
General Discussion  
The study presented in this dissertation was designed to (1) dissect E2 mediated signal 
mechanisms that are important for cell survival and, (2) analyze the significance of pro-
apoptotic, BH3 domain only protein BAD in breast cancer cell survival and proliferation, 
in an in vitro breast cancer model.   
 
3.1 Importance of BAD in E2 Mediated Anti-Apoptosis 
E2 is known to support cell survival though paradoxical induction of apoptosis has also 
been described.  E2 induced apoptosis in rat embryo fibroblasts stably transfected with 
ERα (163) and MCF-7 cells transfected with Raf-1.  In the latter the mechanisms were 
postulated to be mediated by ERβ and AP-1 transcription factors (89).  Estrogen activated 
p38MAPK leading to apoptosis of ERα -stably transfected Hela cells (298).  In addition, the 
response of neurons to estrogen depends on the ER subtype of the cells; ERβ undergo 
apoptosis, whereas cells with ERα are protected from apoptosis.  Although the 
mechanisms underlying the effect of estrogen are not clear, apoptosis mediated by ERβ 
requires FasL (201).  Decreased proliferation and increased apoptosis are associated with 
Jurkat T lymphocytes exposed to estrogen and decreased BCL2 proteins as well as 
mRNA levels were observed during this estrogen effect (133).  Similarly, the thymic 
atrophy due to thymocyte apoptosis has been described with estrogen treatment (202).  In 
bone tissue, estrogen inhibits bone resorption by directly inducing apoptosis of the bone-
resorbing osteoclasts in an ER dependent manner (137).  Furthermore, induction of 
apoptotic gene E9 was observed in estrogen-treated E8CASS (a MCF7 variant) cells and 
the apoptotic action of estrogen was suggested to be mediated by this molecule (266).  
MCF-7 cells that were long-term estrogen deprived underwent apoptosis in contrast to 
their survival response to estrogen under normal conditions (252) (discussed in 1.1.2 
Introduction).  Analogous findings have been reported in the prostate cancer cell line that 
is normally growth stimulated by androgenic compounds (135), and may constitute the 
common biologic response in hormone-responsive tissues.  Cell death induced by 
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estrogen is not a common phenomenon and occurs in a few cell types in contrast to the 
survival benefits that are observed with many cell types.    
 Most of E2’s actions on cell survival or death have been attributed to gene 
regulation.  Emerging evidence for non-genomic actions of E2 prompted us to examine 
the signaling mechanisms of E2 with respect to regulation of cell survival in MCF-7 
breast cancer cells.  Our study shows that E2 significantly reduces apoptosis induced by 
TNFα, H2O2 and serum withdrawal utilizing signal transduction pathways that lead to 
phosphorylation and inactivation of pro-apoptotic protein BAD.   
 E2 effects on BCL2 family members have been described previously: in cells 
where survival is promoted, E2 increased mRNA (210) and protein levels of anti-
apoptotic BCL2 (57,79) or down regulated pro-apoptotic BAK protein (166).  In contrast 
to regulation of BCL2 and BAK at the transcriptional level, we find that E2 rapidly 
induces phosphorylation of BAD at two serine residues (75 and 99) without altering BAD 
protein levels suggestive of activation of non-genomic signal pathways.  Given the fact 
that pro-apoptotic effects of BAD are decreased by phosphorylation and consequent 
sequestration by 14-3-3 proteins (82), we determined whether E2 induced 
phosphorylation of BAD is important for the anti-apoptotic functions of E2.   
 Apoptotic stimuli used in this study increased cytochrome-C level in the 
cytoplasm and co-treatment with E2 reduced this effect concomitant with improved cell 
survival.  This is suggestive of the restoration of mitochondrial integrity at least to some 
degree in E2-treated cells and may account for anti-apoptotic effects of E2.  In cells 
treated with TNFα and H2O2 the extent of BAD phosphorylation was lower than that 
observed in control cultures implicating the activation of BAD by these apoptotic stimuli.  
Accelerated dephosphorylation of BAD as well as the reduced phosphorylation as a result 
of deactivated survival signals can be presumed under these conditions.  Estrogen 
treatment in this context restored phosphorylation to control levels. These experiments 
along with those demonstrating that E2 prevents apoptosis in cells over-expressing wild 
type but not the double phosphorylation site mutant (S75A/S99A) of BAD suggest that 
BAD phosphorylation has a central role in apoptosis of MCF-7 cells.  Remarkably the 
expression of BAD (S75A/S99A) did not cause apoptosis by itself, suggesting that in 
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addition to phospho-serine mediated cytosolic 14-3-3 binding there may be other 
mechanisms to sequester BAD away from mitochondria.  These mechanisms effectively 
inactivating BAD are counteracted by apoptotic stimuli like TNFα.                     
Importance of BAD in MCF-7 cells was confirmed by using antisense 
oligonucleotides to suppress BAD protein translation and analyzing the effects of 
selected apoptotic agents on MCF-7 cell survival.  Diminution of BAD in MCF-7 cells 
significantly reduced the extent of apoptosis induced by TNFα suggesting that BAD 
phosphorylation/inactivation has a central role in apoptosis of MCF-7 cells in response to 
stimuli like TNFα.  Agents such as TNFα and H2O2 have been shown to exert mixed 
effects on BAD protein levels and phosphorylation.  TNFα increased phosphorylation of 
BAD through PI3-K pathway in neutrophils (63), and in HeLa cells (208) where cell 
survival rather than the cell death was promoted by this agent.  TNFα also induced the 
production of more potent truncated form of BAD in a caspase 3 dependent manner 
leading to apoptosis in Jurkat cells (59).  Similarly H2O2 but not superoxide anion (O2–) 
has been shown to increase BAD protein levels in cardiomyocytes leading to apoptosis 
(281).  Serum starvation may modulate activity of BAD and other apoptosis regulators 
and such effects may be reversed by addition of growth factors or by manipulating signal 
transduction pathways (23,295).  Recent evidence from BAD knockout mice suggests 
that BAD may have an important pro-apoptotic role in cell types such as the mammary 
tissue.  Importance of BAD was especially underscored in apoptosis that occurs in the 
absence of growth factors (222) much like the importance of BAD inactivation in the 
response to E2 which is a well known growth factor to breast cancer cells.  However it is 
also evident that BAD concentration or phosphorylation status could not be used to 
define survival or apoptosis in other cells such as PC12 cells (184).   
 
Estradiol Signals Through Two Interacting Pathways in its Anti-apoptotic Action  
In addition to genomic actions, E2 has been known to exert rapid, likely nongenomic 
actions both in the whole animal and in cultured cells (126,226,265).  Previously, we had 
observed that estrogens require the function of the Ras, mitogen-activated protein kinase 
kinase (MEK)1 and extracellular signal-regulated kinase (ERK) pathway to induce G1/S 
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phase transition (7) and elicit down-regulation of the Cdk2 inhibitor p27kip1 (93). Given 
that E2 is now known to activate kinase-regulated signal transduction pathways in MCF7 
and other cells (192) we have examined potential nongenomic pathways involved in its 
anti-apoptotic actions, in particular the PI-3K/Akt and ERK/RSK pathways, which 
mediate BAD inactivation and favors cell survival.  The ability of dominant negative Akt 
or PTEN to reverse the protective effects of E2 suggests an essential role for signal 
transduction through PI-3K/Akt in E2 action in protecting cells from apoptosis.  Akt is a 
known oncogene and is overexpressed in breast cancer cell lines when compared to 
untransformed breast epithelial cells, as well as in breast cancer specimens where the 
majority of cells are ER positive (261).  Given the importance of PI-3K/Akt pathway to 
anti-apoptotic action of E2 (194,211) we examined aspects of this pathway, which might 
influence cell survival.  Our results clearly indicate that PI-3K/Akt has a critical role in E2 
action as a survival agent and a rapid and sustained activation of Akt in response to E2 
was found.  Prolonged activity of Akt may be required to maintain BAD phosphorylation 
at S99 as well as to maintain GSK3β in the inactive state.  Active GSK3β is required to 
stabilize cyclin D1 (77) and increased cyclin D1 protein is a characteristic response to E2 
in MCF-7 and other estrogen responsive cell (94 and refs there in).  E2 signaling has also 
been shown to closely associate with the PI-3K/Akt pathway in vascular endothelial cells 
(120) and ERα is phosphorylated by activation of the PI-3K/Akt pathway in MCF-7 cells 
in the absence of E2 (43,259).  These studies provide insights to growth factor induced 
signal mechanisms that couple and converge the genomic and non-genomic effects of 
ER.   
 In addition to Akt-mediated signaling, our data demonstrate that E2 may also 
signal through Ras/ERK/p90RSK pathway since endogenous and exogenous BAD were 
effectively phosphorylated at S75, a well-known ERK/p90RSK phosphorylation site (82) 
in E2-treated cells.  Our studies with activating and inactivating Ras mutants provides 
strong evidence for this line of argument and show that BAD S75 is a target of Ras-
mediated MEK/ERK activity.  We could directly demonstrate that E2 is able to activate 
p90RSK1 a downstream target of ERK1 and 2 (31,300).  Although the ability of E2 to 
activate ERK remains controversial (47,176,251), ERK activation seems to be important 
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in the apoptotic response (90,241) perhaps through the regulation of BAD 
phosphorylation via p90RSK.  The prolonged activation of ERK in contrast to transient 
activation reported by others (192) may be important to maintain the phosphorylation and 
inactivation of BAD, acting in concert with Akt.  It is also possible that BAD can be 
phosphorylated by kinases other than Akt and p90RSK and that such phosphorylations 
may enhance or diminish the pro-apoptotic capacity of BAD (80,111,150,175).  The two 
signaling pathways that are described here may function as separate entities or interact in 
order to mediate E2 effects.  Previous studies have shown that Ras/ERK and PI-3K/Akt 
exhibit regulatory cross-talk (240,286,297).  Regulation of ERK by E2 through the PI-
3K/Akt pathway has not been previously reported to our knowledge.  Using both 
biological and chemical inhibitors we found that PI-3K may be required not only for E2, 
but also, for IGF-1 induced ERK activation as well as BAD phosphorylation at S75, a 
likely target of the ERK/p90RSK pathway.  Therefore it is likely that E2 regulates ERK 
activation, in part, through PI-3K pathway and our data suggest that E2 regulates a step 
upstream of PI-3K, possibly Ras function (230).   
Expression of dominant negative Ras (RasN17) on the other hand interfered with E2-
induced BAD phosphorylation on both serine residues without affecting the basal BAD 
phosphorylation or protein levels supporting the notion that E2 regulates PI-3K through 
Ras (145).  However we cannot exclude the possibility that E2 may regulate another 
kinase, which can phosphorylate BAD on S99.  The ability of RasN17 to induce 
apoptosis in proliferating cells suggests that Ras plays a critical role in preventing 
apoptosis in MCF-7 cells as observed in other cells (289).  Since 3’4’5’ or 3’4’PI 
phosphates regulate a variety of signal pathways such as Akt and PDK that could lead to 
modulation of Ras/Raf/ERK pathway (221), non genomic signaling by E2 may be quite 
complex (168).  Furthermore, activation of PI-3K by E2 through a direct interaction of the 
p85 subunit with ERα was reported in human vascular endothelial cells (243) and MCF-7 
cells (261).  Clearly further studies are needed to delineate signaling mechanisms and 
their interactions in the perspective of estradiol’s anti-apoptotic and cell cycle effects.   
The non-genomic signaling of E2 is postulated to be mediated by membrane 
associated ER (141) and this hypothesis is further supported by the recent demonstrations 
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of membrane located ERα in MCF-7 and other cell types (185,216).  According to these 
authors the fraction of plasma membrane bound ERα ranged from 3-20% of the total in 
MCF-7 cells.  Agreeing with this notion our data shows that E2 induced rapid ERK 
phosphorylation and the protective effects against apoptotic agents was substantially 
blocked by the anti-estrogen ICI 182,780.  
 
3.2 BAD Has a Role in Cell Cycle Regulation  
Above findings clearly define a role for BAD in E2 mediated anti-apoptosis in breast 
cancer cells.  To extend our knowledge on BAD regulated cell survival and function to 
another level, we assayed the transcriptional activities of BAD in the context of cell cycle 
progression as our data indicated the presence of BAD in the nucleus.       
Cell proliferation and apoptosis are two major pathways that are important for the growth 
and development of a multi-cellular organism.  The natural interdependency of these two 
key mechanisms keeps the tissue mass to a balance i.e. increased proliferation 
consequently triggers cell death through apoptosis and other programmed cell death 
process, where as reduced cell death is of no significance in the absence of enhanced 
proliferation.  Just as cell death shapes tissue remodeling or development, cell death also 
maintains the course and nature of the immune response.  Lymphocytes mediated, 
immune-directed programmed cell death provides a mechanism that is the basis for self-
versus non-self discrimination and potentially the immnuorecognition and removal of 
damaged or cancerous cells (discussed in 1.1.1 Introduction).   
Multitasking proteins such as Ras, Myc and c-Jun have been shown to participate 
in both cell proliferation and cell death and, our data strongly indicate a novel role for 
BAD in cell cycle control.      
 
The concentration of BAD modulates cell cycle progression 
Under normal conditions, BAD is phosphorylated on S75 and S99 and bound by the 14-
3-3 like molecules a measure to reduce the sensitivity to apoptotic signals (71).  
However, there is a substantial amount of unphosphorylated BAD in a normal cell and 
the cytoplasm appears to be the major location for both forms.  Known pro-apoptotic 
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functions of BAD mostly occur in the cytosol or the mitochondria.  Localization of 
endogenous BAD in breast cancer cell nuclei strongly suggests an existence of a 
currently unknown reserve of this molecule.  When present in an excess amount, BAD 
prevented cell cycle progression in response to growth factors and E2, where as, BAD 
knockdown enhanced the cell cycle entry in a time dependent manner.  A negative 
regulation on cell cycle by BAD is plausible in an unstimulated cell, since the reduction 
of BAD improves the progression from G1 to S.  The observation that was made with 
BAD over-expression could then be an exaggerated or magnified effect of this normal 
endogenous effect of the molecule.     
 Similar phenomenon has been observed with BCL2 and BCLxl in malignant as 
well as normal epithelial cells.  When overexpressed, BCL2 arrests cells in G0/G1 phase 
and this effect depends on the amino terminal BH4 domain (121).  Interestingly in a 
variety of epithelial cell types, endogenous BCL2 was shown to localize to the 
chromosomes of mitotic nuclei (180).  This pattern of BCL2 expression can be 
considered as an indicative of its special role in cell proliferation.  Mutation of the 
conserved tyrosine residue within the BH4 domain of BCL2 and the equivalent residue 
Y22 in BCLxl eliminated their ability to delay S phase entry with out affecting the ability 
to inhibit apoptosis (125), leading to the conclusion that anti-apoptosis functions of these 
proteins can be genetically separated from their cell cycle function.  The cell cycle delay 
effect of BCL2 and BCLxl has been measured as lengthened time to reach S phase from 
quiescence, which results from enhanced G0 arrest or delayed transit through G0-G1 
(132).  The reduction in S/G2 fraction concomitant with increased G1/G0 fraction in 
BAD overexpresing, asynchronously growing cells suggests the retardation of the 
passage from the latter.  MCF-7 cells that are synchronized in G1 by anti-estrogen and 
low serum readily progress into S phase upon mitogenic stimuli (94) and this response is 
also reduced due to excess amounts of BAD.  Studies are underway to clearly identify the 
exact location of the cell cycle arrest due to BAD under these conditions.  Extending our 
analysis to normal mammary epithelial cells, we should be able to evaluate the 
physiological relevance of BAD’s effect on the cell cycle.      
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Cyclin D1 regulation by BAD through AP-1 proteins and their binding elements  
Regulation of cell cycle in ER+ breast cancer cell line MCF-7 has been extensively 
studied and the information on mitogenic effects of E2 and other agents on these and 
other breast cancer cells are abundant (7,94,95).  Cyclin D1 plays an important role at the 
G1 to S transition upon a mitogenic signal (94) and has been implicated as a 
diagnostic/prognostic marker of breast cancer.  Transcription of the cyclin D1 gene and 
the stability of the gene product are tightly regulated hence the function of the molecule.  
Members of the AP-1 transcription factor family, particularly c-Jun has been shown to be 
involved in the transcription control of cyclin D1 (discussed in Chapter 2.1).  c-Jun 
induces mRNA and protein levels of cyclin D1 in response to proliferative signals, which 
correlates with the progression of cell cycle.  However, cell cycle defects in c-Jun-/- cells 
were only partially (30%) relieved by the overexpression of cyclin D1 suggesting that 
cyclin D1 is not the only target of c-Jun in this context.   
An increased expression of cyclin D1 protein was observed in the BAD knockdown 
conditions, which correlates with the increased G1 to S transition.  An inhibitory effect 
on the cell cycle by BAD or its down stream target/s could have been revoked by the 
decrease in BAD, resulting in this proliferative effect.  This hypothesis is further 
supported by the overexpression studies where an increased amount of BAD abolished 
the cyclin D1 level in response to mitogens.  De novo synthesis of cyclin D1 was 
markedly reduced under excess BAD expression, which is likely to contribute to the 
above observation.  However, BAD’s influence on the stability of the cyclin D1 protein 
cannot be ruled out.  
The signal axis of c-Jun activation to cyclin D1 expression in MCF-7 cells 
appears to be obliterated by BAD as phosphorylation dependent activation of c-Jun and 
the upstream kinases were significantly reduced by its overexpression.  BAD’s influence 
on signaling pathways have not been described to date and require further studies.  The 
activity change without a change in the expression levels strongly suggests a non-
genomic action on these signal molecules by the excessive amount of BAD, presumably 
accelerated dephosphorylation.  As per our hypothesis that the effects of exogenous BAD 
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are the exaggerated endogenous effects, the site of this action of BAD needs to be 
identified.   
BAD’s influence on c-Jun appears to be two fold since in addition to inhibiting its 
phosphorylation, BAD binds to the unphosphorylated or transcriptionally inactive c-jun 
in the nucleus.  Additional to the known regulatory mechanisms that govern the level of 
phospho c-jun available for gene transactivation, BAD may function as a sequestering 
entity for c-jun thereby preventing it being phosphorylated by activating kinases, under 
normal conditions.  The significance of this interaction can be postulated by the extent of 
BAD bound c-jun in the nucleus, which is approximately 10-15%. 
Regulation of cyclin D1 in response to E2 is mediated through AP-1 binding DNA 
elements such as TRE and CRE (Chapter 2.1 Introduction).  Our studies exploring the 
transcriptional and translational control of cyclin D1 in BAD over-expressing cells show 
that BAD indeed negatively regulates the de novo synthesis of cyclin D1and the cyclin 
D1 promoter activation.  Assay of cyclin D1 promoter –reporter constructs where AP-1 
protein binding sites have been mutated (structure of cyclin D1 promoter, Figure 
2.1.2.1B) shows that BAD’s influence is essentially mediated through the CRE rather 
than AP-1/TRE in this natural promoter, an observation that agrees with the suggested 
critical role for CRE in cyclin D1 transcription in breast cancer cell (115).   
 Using minimal AP-1 binding DNA sequences in electro mobility shift (EMSA) 
and reporter assays, we further evaluated the inhibitory effects of BAD on AP-1 protein 
and DNA interaction.  Level of BAD in the cell appears to influence the efficiency of this 
interaction in MCF-7 cells.  When present in an excessive amounts BAD significantly 
reduces this interaction to an extent that is comparable to the dominant negative c-Jun.  
An increased protein-DNA interaction was observed under BAD knockdown condition in 
vivo and in vitro.  Further, BAD over-expression markedly reduced the TRE-luciferase 
activity, which is dependent on the direct interaction of AP-1 nuclear factors and TRE 
sequence, in asynchronous and E2 induced cells.  Availability of active AP-1 transcription 
factors is critical to ensure proper DNA binding in above conditions and inhibition or 
unavailability of these factors can be presumed, to result in decreased DNA biding when 
BAD is present.  This data clearly suggest a regulatory role for BAD, upstream to AP-1 
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protein and DNA interaction, an effect that is physiologically manifested by the cell cycle 
blockade.             
 
BAD Effects on Cell Cycle regulation depend on its phosphorylation  
It is well established that, when phosphorylated on two serine residues (S75 and S99) 
BAD is inactive in respective to its pro-apoptotic function (Chapter 1.1.3 Introduction).  
Agreeably, our data demonstrate the dephosphorylation-mediated activation of BAD by 
apoptotic agents and the restoration of BAD phosphorylation during the E2 induced anti-
apoptosis.  Further, BAD dephosphorylation (achieved by knocking in the 
unphosphorylatable mutant of BAD) sensitized mice and mouse embryonic fibroblasts to 
apoptosis induced by death receptor signaling and DNA-damaging agents (71).  
Together, all above information suggest that BAD phosphorylation and 
dephosphorylation specifically regulate the response to apoptotic stimuli that involve 
mitochondrial dysfunction and, phosphorylated BAD is a critical mediator of survival 
signals in cells.  Our data also suggest the critical involvement of BAD phosphorylation 
in its cell cycle regulatory function.  Analogous to this, mono-site or multi-site 
phosphorylation of BCL2 in the flexible loop region enhanced its anti-apoptotic effect 
and retarded the cell cycle progression (74).  This observation refutes the previous notion 
that the anti-apoptotic and cell cycle effects of BCL2 are functionally separable (121), 
and links these two functions through phosphorylation.  Similarly, in the case of BAD, 
pro-apoptotic and cell cycle regulatory effects appear to be linked by phosphorylation.  
In the context of nuclear/transcriptional effect, the phosphorylated or 
‘apoptotically inactive BAD’ is notably important.  The cell cycle block subsequent to the 
regulatory effects on AP-1 functions, observed with wild type BAD were not readily 
visible with the dual phosphorylation site mutant of BAD in which S75 and S99 are 
mutated to unphosphorylatable alanine despite the satisfactory expression level of this 
molecule.  In contrast, BH3 domain mutant, which retains the intact S75 and S99 was as 
effective as the wild type BAD.  A step subsequent to BAD phosphorylation is likely to 
mediate another AP-1 regulatory effect in addition to BAD mediated binding and 
sequestration of c-Jun in the nucleus.  Inactivation of c-Jun activating kinases by the 
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overexpressed, phosphorylatable wild type BAD but not the phosphorylation site mutant 
supports the supposition that BAD regulates these signal transduction pathways in a 
phosphorylation dependent manner.     
At least 50% of the cells that overexpressed wild type BAD were able to counter 
apoptotic stimuli when E2 was present and these E2 induced survival effects are partly 
mediated by Ras/ ERK signaling pathway.  On the other hand, accumulation of BAD 
(through transient overexpression) in the cells over a period of time (> 72 hrs) was 
important to render cells unresponsive to mitogenic signals of E2, that are also partly 
mediated by ERK mediated signaling mechanisms.          
 
3.3 Summary 
This study demonstrates that E2 inhibits apoptosis in MCF-7 cells by enhanced 
phosphorylation of BAD, and indicates that BAD inactivation results from activation of 
Ras/ERK/p90RSK and Ras/PI-3K/Akt pathways by E2.  Data also indicate that BAD plays 
an essential role in apoptosis induced by H2O2, TNFα and serum withdrawal.  
Interestingly, data also indicate that even the double phosphorylation site mutant of BAD 
(S75/99A) is inactive as an inducer of apoptosis in the absence of an apoptotic stimulus 
(Figure 3.1), an observation that agrees with the BAD knockout study (71) where the 
knocked in BAD S75/99A mutant did not induce death in mouse or MEFs rather 
sensitized them to apoptotic agents like TNFα and growth factor withdrawal.      
 BAD also plays a decisive role when breast cancer cells have to respond to 
mitogenic signals.  Its negative influence on AP-1 mediated cyclin D1 expression may 
play an important role to maintain the correct level of cell cycle progression under normal 
conditions.  For a successful mitogenic response to occur, BAD’s negative regulation 
needs to be decreased, possibly by dissociating BAD/c-Jun interactions that may be 
found proximal to chromatin (Figure 3.2).  When mitogen fails to counteract the 
enhanced negative regulation of cell cycle by elevated levels of BAD, cells may submit 
to reduce proliferation and subsequently programmed cell death.  The interplay of above 
discussed factors can be summarized by the scheme shown in Figure 3.3.     
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Figure 3.1
Mechanisms that  mediate E2 induced anti-apoptosis 
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Figure 3.3
Proposed outcomes due to E2 and BAD interaction in MCF-7 cells
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3.4 Prospects 
Identification of genomic targets for BAD  
Effects of exogenous BAD on AP-1 binding elements in cyclin D1 natural promoter 
warrant further investigation of genomic targets of BAD.  This can be approached in 
several different ways.   
 (1) DNA sequences that bind with BAD (directly or indirectly) can be isolated by 
the Chromatin immuno precipitation (ChIP) coupled with BAD specific antibody.  In this 
method protein/protein and protein/DNA are reversibly cross-linked and 
immunoprecipitated with BAD specific antibody.  The resulting complex can be used to 
detect interacting proteins as well as nucleic acid sequences.   
 (2) Gene targets that are up or down regulated due to BAD overexpression can be 
analyzed by Gene array technique.  The arrays tailored for specific pathways are 
commercially available.        
 
Significance of BAD phosphorylation in cell cycle regulation   
Failure of the unphosphorylatable BAD mutant to suppress cell cycle progression calls 
for further verification of the role of these phosphorylation sites.  Phospho-mimicking 
(serine sites mutated to glutamate or aspartate) mutation to BAD can be used to address 
this issue.  If the cell cycle suppression and the up stream effects on c-Jun and cyclin D1 
can be restored by these mutations, a precise role of BAD phosphorylation can be 
defined.   
 
Significance of BAD and c-Jun interaction in cyclin D1 expression 
BAD and c-Jun interaction at the nuclear level was demonstrated by immunoprecipitation 
assays.  Similarly, BAD depletion from nuclear extract reduced the AP-1/TRE and 
nuclear factor interaction to an extent that is comparable to that of dominant negative c-
Jun.  Sequestration of c-Jun by BAD can be deduced from these observations and can be 
further verified by mammalian two-hybrid technique, where BAD and c-Jun can be 
cloned into bait and target vectors respectively.  In addition to c-Jun, other presumed AP-
1 molecules can be used as targets in this technique.   
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Further, mutant forms of either molecule can be used to define the critical domains or 
residues that are necessary the interactions.   
 
BAD influence on signal mechanisms  
Overexpression of wild type BAD abolished ERK and JNK signaling in response to 2-3 
hr treatment of E2 and serum respectively.  We also found that the ERK response for E2 is 
bi-phasic (transient/rapid and sustained) and the rapid phase signal is presumed to 
inactivate BAD’s apoptotic effects whereas the sustained signal may be required for the 
mitogenic effect.  Our data suggest a role for BAD as a regulator for the second phase of 
E2 induced ERK signaling, that is reflected by its effects on cell cycle progression.  
Detailed kinetics of E2 induced ERK signaling under the conditions of BAD over-
expression and knockdown is desired.   
Accelerated dephosphorylation of these molecules by BAD is likely and, the activities of 
phosphatases need to be assayed.  Within the cells, the interacting signal molecules are 
mostly found in clusters (enzyme and substrate docking via special domains) and BAD’s 
role in modulating these interactions can be analyzed.       
 
Generation of cell lines that express BAD (wild type and mutants)  in a regulated 
manner 
Cells that stably express the desired molecule are more advantageous than transient 
expression.  When a stable expression is under a regulated promoter (e.g. tetracycline 
responsive) the molecule can be expressed at desired levels and the effects can be 
analyzed.  Cell lines that express BAD (wild type and mutants) in a regulated manner can 
be very useful to carry out various experiments that have been suggested above.   
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Chapter 4 
Materials and Methods 
 
4.1 Cell Culture 
MCF-7 cells (a gift from R. P. Shiu (84)) were cultured in Dulbecco’s modified Eagles’s 
medium (Sigma St. Louis, MO) supplemented with 5% fetal bovine serum (FBS), 
penicillin G and streptomycin at 37° C in 5% CO2.    
T47D (ATTC) were grown in DMEM/F12 (1:1) supplemented with 5% fetal serum, 
penicillin G and streptomycin at 37° C in 5% CO2.   
 
Growth arrest  
Complete serum/growth factor withdrawal 
Cells (MCF-7) were kept in 1% FBS for 24 hrs in DMEM (phenol red [PR] free) medium 
and completely serum withdrawn for additional 36-48 hrs before the experiments.   
Using anti estrogen and low serum 
Cells (MCF-7 and T47D) were kept in 10nM ICI182,780 and 0.2% FBS for 48 hrs.  Both 
these methods arrested cells at G1 (at least 80% of the population was found to be in G1 
as measured by DNA profiling using flow cytometry). 
 
Treating growth arrested cells  
Prior to treatments, cells were washed once with warm PBS and treated in medium free 
of serum and PR. 
LY294002 (5µΜ in MTT assay, 20µΜ in other assays), PD98059 (50µM)  [Sigma] and 
ICI182, 780 (1µM) [gift from Zeneca Pharmaceuticals], were used alone or added 1 hr 
prior to other growth factors and E2.   
E2 was used at 1nM in MTT assay and 10nM in other assays. 
IGF-1 was used at 10ng/ml.  Cells were treated with DMSO or EtOH as vehicle controls.    
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4.2 Transient Expression of Desired Molecules with Adenoviral and 
Plasmid Vectors 
Adeno viruses 
PTEN and DnAkt [kind gifts from Drs. R Bookstein, (53) and K Walsh (157) 
respectively] and control vector LacZ [Q.Biogene - Carlsbad, CA] were transduced at 60, 
30 and 30 MOI respectively.  Optimum MOIs were determined by analyzing DNA 
profiles (by flow cytometry) in response to virus dosage.   Cells at 20-30% confluence 
were infected in complete growth medium for 2 hrs.   After the infection, cells were 
recovered for 3-6 hrs in growth medium; growth arrested and treated as desired.  To study 
DNA fragmentation with TNFα or H2O2, cells were maintained in DMEM (PR free) with 
2.5% FBS for 48 hrs after infection followed by induction of apoptosis.  
 
Plasmids 
Cells were transfected with various plasmid vectors using Lipofectamine PlusTM reagent 
according to the manufacture’s [Invitrogen, Carlsbad, CA] protocol.  Fifty to 80% 
transfection efficiency was obtained as determined by the expression levels of EGFP 
(microscopic and flow cytometry analysis).   
Following is a list of plasmids used in this study.  
Flag tagged human BAD wild type (wt) and human BAD serine75 and serine99 
(equivalent to mouse serine112 and serine136 respectively) mutated to alanine were 
kindly donated by Dr. HG Wang (119)   
GFP tagged human wtBAD  
RasN17, RasV12T35S (kindly donated by Drs. G L Johnson and C M Counter (110) 
respectively) 
AP-1 luciferase (kindly donated by Dr. Ben Dibling 
Tetracycline response element (TRE) luciferase (ClonTech) 
Human c-jun (kindly donated by Dr. Anders Strom) 
Myristylated AKT (kindly donated by Dr. Antonio Cuadrado) 
Cyclin D1 promoter luciferase constructs (kind gift from Dr. Pestell) 
 v-jun (Kindly donated by Dr. Vogt)    
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4.3 Endogenous BAD Knockdown  
Using BAD anti-sense oligonucleotides  
BAD antisense oligonucleotides with phosphorothioate linkages were synthesized and 
purified by Sigma-Genosys, Woodlands, TX.  Cells were transfected twice (48 hrs apart) 
with Lipofectamine Plus TM or RNAifect reagent according to the manufacture’s 
[Invitrogen, Carlsbad, CA] protocol.   Transfections were carried out in 6 well plates 
using 1−3 µg of oligonulceotide per well.  Antisense oligonucleotides used in this study 
encoded complementary sequences to the coding regions including translation initiation 
(BAD antisense 1) and termination codon (BAD antisense 2) sites for the human BAD 
gene.  Oligonucleotide sequences used were BAD antisense 1; 5’-
TGGGATCTGTAACATGCT-3’, BAD antisense1 (scrambled/control); 5’-
GGTTAGGTCAATTACTCG-3’, BAD antisense 2; 5’- CGAAGGTCACTGGGA-3’.   
 
Using BAD siRNA 
For the RNA interference siRNA for human BAD was purchased from Cell Signal 
Technology (Cat# 6471).  Transfection was done at the final concentration of 33nM of 
siRNA with RNAifect according to the manufacturer’s protocol.      
  
4.4 Cell Survival Assay using MTT 
3-4,5-dimethylthiozol-2, 5-diphenyl-tetrazolium bromide (MTT) was used to measure the 
amount of functional mitochondria hence the amount of live cells.   
At 20-30% confluence, cells were treated in triplicates in 24 well plates.  At 24 hr 
intervals, MTT assay was performed according to the manufacture’s [Sigma] protocol.  
Briefly MTT (5mg/ml) was added to equal one-tenth of the culture volume, and followed 
by incubation for 3 hrs.  Medium was removed and the converted dye was solubilized in 
ice-cold isopropanol.  Absorbency of dye was measured at 560nm with background 
subtraction at 630nm on a micro plate reader [EL 340 Bio Kinetics Reader- BIO-TEK® 
instruments].   
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4.5 Induction and Assessment of Apoptosis  
(1) Apoptosis was induced with H2O2 (2mM) for 1.5 hrs, TNFα (10ng/ml) for 8 hrs or by 
complete serum withdrawal for 72 hrs, or with indicated constructs (where appropriate).  
Cells were pretreated with E2 or IGF-1 for 1 hr prior to apoptotic stimuli.   
ELISA assay kit [Cell death ELISA, Roche Diagnostics, Indianapolis IN] was used with 
slight modification to the manufacture’s protocol to quantify DNA fragmentation.  
Briefly, 50,000 cells (of each treatment) were lysed in 100µl of lysis buffer and a fraction 
of the supernatant was subjected to reaction for 2 hrs with the immunocomplex of anti-
DNA-conjugated with peroxidase which binds to nucleosomal DNA, and anti-histone-
biotin which interacts with streptavidin-coated wells in a micro titer plate.  At the end of 
the incubation, substrate was added and color development was quantified at 405nm 
wavelength.  
(2) DNA content was analyzed by flow cytometry and the sub G1 population was 
considered as apoptotic (203). 
 
4.6 Microscopic Analysis of Fluorescent-labeled Cells (fluorescence and 
confocal microscopy)          
Cells grown on cover slips were, transiently transfected with (i) indicated vectors and 
green fluorescent protein (EGFP, 15% of total DNA) for co-expression studies (we have 
previously validated the co-expression of plasmid constructs in MCF-7 cells (93)), (ii) 
Flag tagged constructs, or left untrasfected.  All trasfections were carried out using 
Lipofectamine PlusTM reagent.   
For anti-body staining: cover slips were fixed in 3% paraformaldehyde in PBS, 
permeabilized with 0.1% Triton X-100 (in PBS) and blocked with (100% goat serum and 
1% BSA) for 30 min at room temperature.  Cover clips were incubated with primary 
antibody solutions (made in blocking buffer according to the manufacturer’s instructions) 
overnight at 40C.  Cover slips were washed 5 times with PBS incubated with fluorescent 
conjugated secondary antibodies for 2 hrs at room temperature.  After washes with PBS 
nuclei were stained with 3 µg/ml Hoechst 33342 [Sigma St. Louis, MO].  Cover slips 
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were mounted on to glass slides and analyzed using a fluorescence microscope (Leitz 
DMRB) or the confocal microscope.   
For EGFP expressing cells: cover slips were fixed and nuclei were stained as above.   
 
4.7 Western blot Analysis  
Cells were washed once with ice-cold PBS and lysed in buffer containing 50mM Tris-
HCl, 1% NP-40, 0.25% sodium deoxycholate, 150mM NaCl, 1nM EGTA, 1mM PMSF, 
1µg/ml leupetin, 1mM NaVO3, 1mM NaF.  
For PARP cleavage detection, cells were lysed in ice-cold buffer containing 50mM Tris-
HCL, 6.5M Urea, 5% mercaptoethanol, 2% SDS and protease inhibitors; sonicated for 20 
seconds and briefly centrifugated to remove cell debris (292). 
For cytochrome-C detection, cytosolic fraction was prepared as described under ‘cell 
fractionation’.      
Aliquots of cell extracts containing 50-100 µg of total proteins or immunoprecipitates of 
the indicated proteins were resolved on SDS-PAGE, transferred to nitrocellulose 
membranes and probed with specific antibodies to phospho ERKs (pTEpY) [Promega-
Madison, WI], phosphor BAD (S112 and S136) [Upstate Biotechnology-Lake Placid, 
NY], ERK2, PTEN, BAD, PARP, cytochrome-C, Ras, phospho c-jun, cyclin D1, Akt 
[Santa Cruz Biotechnology-Santa Cruz, CA] and c-jun [Neomarkers],  followed by the 
appropriate secondary antibody conjugated with HRP [Santa Cruz Biotechnology].  
Proteins were detected by ECL™ [Amersham Life Science Ltd-Piscataway, NJ] and 
examined by X-ray films.  The band intensities/ fold activities were measured by Sigma 
Gel™ software [Jandel Scientific-Winooski, VT].   
 
4.8 Cell Fractionation 
Nuclear and cytosolic fractions 
Cytosolic and nuclear fraction were prepared as described in (119) with some 
modifications.  Cells (~10 million cells) were suspended in 150µl of hypotonic buffer 
containing 3.3mM Hepes, pH7.5, 1.7mM KCl, 0.25mM MgCl2, 0.2mM EGTA, 0.2mM 
EDTA, 5µg/ml leupeptin, 0.3mM PMSF, 16.7mM NaF, 66.7µM Na3VO4 and 8.3mM 
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sodium β-glycerophosphate.  After incubation on ice for 30 min, cells were homogenized 
with a Dounce homogenizer and centrifuged at 1000g for 5 min at 4°C to collect the 
nuclei. The resulting supernatant was centrifuged at 10000g for 10min at 4°C to obtain 
the heavy-membrane fraction (pellet) and the cytosol (supernatant). 
The nuclear pellet was resuspended in 50µl of buffer containing 20mM Hepes pH7.5, 
1.5mM MgCl2, 420nM NaCl, 0.2mM EDTA, 25% v/v Glycerol, 0.3mM PMSF and 
5µg/ml leupeptin, and incubated on ice with vigorous agitation (using small magnetic 
bar) for 30 min.  Nuclear extract (supernatant) was recovered after centrifugation at 
5000g for 10 min at 4°C.   
 
4.9 Immunocomplex Kinase Activity Assays 
Radioactive method 
Antibodies against ERK2, Akt, GSK3β, p85 (PI-3K) and protein A/G plus beads were 
purchased from Santa Cruz Biotechnology.  Anti p90RSK1antibody, soluble BAD and 
IRS-1 were purchased from Upstate Biotechnology-Lake Placid, NY.  Myelin Basic 
Protein (MBP) was from GIBCOBRL-Carlsbad, CA. 100-200 µg total protein was 
immunoprecipitated with antibody in excess and protein A/G plus beads at 4°C 
overnight.  Precipitates were washed three times with TG buffer (250mM NaCl, 20mM 
Tris, 0.5% NP 40) and once with kinase buffer (50mM Hepes pH 7.4, 15mM MgCl2).  
Kinase reactions were performed by incubating immunoprecipitates and the specific 
substrates (0.2-1µg per sample) in kinase mixture (20µM ATP, 5µCi (γ 32P) ATP, 1mM 
dithiothreitol and 0.1 mM Na3VO4 in kinase buffer) for 30 min at room temperature.  
Reactions were stopped with 4X Laemmli’s sample buffer and proteins were resolved on 
SDS-PAGE.  Band intensities of phosphorylated substrates in autoradiograms were 
measured by densitometry.   
 
Phosphorylation assay (non-radioactive) with BAD GST fusion proteins  
 p-GEX-BADwt/mutant  (kindly donated by Drs. P Cohen, (175) and AM Tolkovsky(279)) 
were grown in E.coli and proteins were isolated using glutathione-agarose beads (Sigma) 
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followed by elution in the presence of reduced glutathione.  Ten µg of BAD protein was 
incubated with 75 µg of whole cell lysate in 50 µl of kinase buffer in the presence of 
25µM ATP for 30 min in room teperature.  At the end of the reaction 15 µl of agarose 
conjugated glutathione was added and shaken for 1 hr at 4°C.  Beads were collected, 
washed three times with TG buffer and resuspended in 25 µl of 2X Laemmli’s sample 
buffer. 
 
4.10 Electrophoretic Mobility Shift Assay (EMSA) 
Nuclear extracts for EMSA was prepared as described above (3.8).  Gel Shift assay 
system (Cat# E3300) was purchased from Promega (Madison, WI).  The AP-1 and 
control elements were labeled with (γ-32) ATP and non denaturing 4% acrylamide gels 
were prepared according to the manufacture’s protocol.  DNA binding reactions were 
carried out using 50µg of nuclear extract, radio labeled probe and gel shift binding buffer 
with relevant volume of nuclease free water as described by the manufacturer.  At the end 
of the incubation period, reactions were resolved on non-denaturing acrylamide gel.  Gels 
were dried and auto-radio grams were obtained.                  
 
4.11 Reporter Assay 
AP-1/TRE and cyclin D1 luciferase constructs were expressed in MCF-7 and T47D cells 
as described in results and figure legends.  After the desired periods of expression, cells 
were rinsed with PBS and lysed with minimal volume of 1X reporter lysis buffer 
(Promega Cat#E3971) [100 µl of lysis buffer for 1 well of a 6 well plate] on ice for 10 
min.  Supernatant was collected after brief centrifugation (12,000g for 2 min at 40C).  50 
µl of cell lysate and 100 µl of Luciferase Assay Substrate (Promega Cat#E4030) were 
mixed and emission of light was measured using the scintillation counter.  For 
consistency in measuring luciferase activity, each sample reaction was initiated 
immediately before the measurement and reading.  To measure the level of luciferase 
vector expression, EGFP was co-expressed and EGFP levels were analyzed by the 
Western blotting.                     
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 4.12 DNA Profile by Flow Cytometry Analysis 
Single cell suspension of harvested cells was fixed in 70% cold ethanol, pelleted and 
washed with PBS.  Cells were then incubated in propidium iodide staining solution 
(1µg/ml) in the presence of RNAse in PBS for 30 mins to 1 hr at room temperature, in 
dark.     
      
4.13 Metabolic labeling with 35(S) methionine 
MCF-7 cells were transiently transfected with desired constructs.  Twenty four -48 hours 
after the transfection, cells were cyctine/methionine deprived for 1 hr (methionine free 
Dulbecco’s MEM/F12) and labeled with Trans 35S (75µci/ml) in the same medium for 
desired period of times.  Labeling medium was removed and the cells were washed twice 
with cold PBS.  Cells were lysed and indicated proteins were immnuoprecipitated from 
whole cell extracts.  Immunoprecipitates were resolved using 12% SDS-PAGE.  Gels 
were dried and exposed to X-ray film.  Intensity of the band denotes the amount of 35S 
methionine incorporated within the labeling period.           
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